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ABSTRACT 
The role of hemodialysis nurses in renal anemia management has evolved through the 
implementation of nurse-driven protocols Using the Nursing Role Effectiveness Model, this 
case control study examined a nurse-driven renal anemia management protocol approach in 
contrast to a physician-driven approach to assess patient outcomes and costs of renal anemia 
management from two comparable hemodialysis centres Both protocol and control groups 
achieved target hemoglobin levels between 110-120 g/L In the protocol group, 75% of 
patients reached TSAT >20% versus 25% in the control group Iron costs were $17,000 
higher in the control group over the study period The protocol group used more epoetin alfa, 
trending upwards to approximately 10,000 units per person by the end of the study with over 
$8 000 per person higher costs compared to the control group Evaluation of standardized 
dosing in renal anemia treatment is suggested for patients with diabetes or cardiac co-
morbidities 
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Erythropoietic stimulating agents 
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Kidney Disease Outcomes Quality Initiative, recognized as the 
international standard for evidenced-based clinical practice guidelines for 
all stages of chronic kidney disease, developed by multidisciphnary 
nephrology experts 
Kelowna Renal Program serves the Okanagan Health Services Delivery 
Area with hemodialysis sites in Kelowna, Rutland and Vernon, British 
Columbia 
Northern Health 
Nursing Role Effectiveness Model, A structure-process-outcome nursing 
model of care developed to examine the contribution that nursing roles 
have on patient outcomes (Irvine, Sidani & McGilhs Hall, 1998) 
The process component identifies three roles of the nurse and 
categorizes these roles based on the functions or activities of the 
nurse, independent, dependent, and interdependent roles 
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• The structure component of the NREM consists of patients, nurses, 
and organizational variables that impact processes and outcomes of 
care 
• The outcome component of the NREM is the patients' health status, 
and the direct and indirect costs associated with nursing care 
• Nurse-sensitive outcomes are patient outcomes that can be 
attributed to nursing practice/actions 
NRP Northern Renal Program serves Northern British Columbia, has 
hemodialysis sites located in Prince George, Terrace and Ft St John, 
British Columbia 
Nurse-driven That which is initiated and directed by nursing practice 
OHDSA Okanagan Health Delivery Service Area 
Physician-driven That which is initiated and directed by physician practice 
PROMIS Patient Records, Outcomes and Management Information System, 
database system adopted by British Columbia Provincial Renal Agency 
Protocol Algorithm using evidence-based clinical practice guidelines 
RAMP Renal Anemia Management Protocol based on BCPRA standards and used 
by the Northern Renal Program 
TS AT transferrin saturation, an indicator of iron status percentage of iron 
saturating iron binding sites on transferrin 
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CHAPTER 1 
Introduction 
Nephrology nurses in the hemodialysis setting are facing new challenges in the health 
care system Greater incidence of chronic kidney disease worldwide, coupled with limited 
financial and human resources in the health care system, have placed significant demands on 
the hemodialysis nurse In response to these demands, hemodialysis nurses are adopting new 
approaches to practice to provide safe, economical and effective care Current trends in the 
hemodialysis setting are placing greater emphasis on enhancing the decision-making role of 
the nurse to provide clinically sound practice and cost effective care in renal anemia 
management Increasingly, protocols based on best practice guidelines are followed in the 
care of the hemodialysis patient The clinical effectiveness of these protocols is commonly 
measured by patient physiological outcomes such as achieving target hemoglobin levels, 
transferrin saturation levels and ferritin levels The cost of protocol care can be examined by 
reviewing the average use of treatments such as erythropoeitin stimulating agents and 
intravenous iron There is little evidence to show whether using or not using a protocol 
affects patient and cost outcomes, or whether these differences in outcomes can be attributed 
to nursing care Using the concepts of structure, process, and outcomes discussed in the 
Nursing Role Effectiveness Model, this study evaluated two approaches to renal anemia 
management Outcomes and costs associated with anemia management for hemodialysis 
patients were examined in two comparable regions within British Columbia (BC) in this case 
control study 
1 
Background and Need 
Incidence and Prevalence of Chronic Kidney Disease 
Chronic kidney disease (CKD) is defined as the presence of kidney damage for 
greater than three months with a glomerular filtration rate (GFR) of less than 60 ml/min/1 73 
m2, with or without evidence of abnormalities in urinalysis, diagnostic imaging or renal 
biopsy (Eknoyan & Levin, 2002, National Institutes of Health, 2008) Table 1 classifies 
CKD into five stages based on GFR level (National Kidney Foundation, 2002) 
Table 1 
Stages of Chronic Kidney Disease 
Stage Description GFR 
(ml/min/m2) 
1 Slight kidney damage with normal or increased filtration >90 
2 Kidney damage with mild decrease in kidney function 60-89 
3 Moderate decrease in kidney function 30-59 
4 Severe decrease in kidney function 15-29 
5 Kidney failure requiring transplantation or dialysis <15 
End Stage Renal Disease (ESRD) 
Note Adapted from, "National Kidney Foundation (2002) Clinical Practice Guidelines for Chronic Kidney 
Disease Evaluation, Classification and Stratification," American Journal of Kidney Diseases, 39 (Suppl 1) 
pSl-S266 
CKD has a significant impact on society and the health care system Chronic kidney 
disease is estimated to affect between 1 9 and 2 3 million Canadians (Levin et al, 2008) 
While there are no statistics available regarding prevalence of CKD in separate regions of 
British Columbia, the overall estimated prevalence of chronic kidney disease is 145,000 
cases (BCPRA, 2008) Patients with CKD have a risk of cardiovascular disease that is ten to 
thirty times higher than those without CKD (Sarnak et al , 2003) CKD is often associated 
with anemia, cardiac disease, hypertension, and diabetes all of which require aggressive 
2 
chronic disease management CKD is correlated with increased length of hospital stay 
thereby having an impact on patients, families, society, and health services (Mix et al , 2003) 
Stage five CKD is also known as end stage renal disease (ESRD) At stage five, renal 
replacement therapy (RRT) is required to extend life (Levin et al , 2008) RRT consists of 
either dialysis or transplantation Hemodialysis and peritoneal dialysis are two forms of 
dialysis treatment In 2006, 82 1% of all new ESRD patients were started on hemodialysis 
treatment (Canadian Institute for Health Information, 2008) 
Etiology of Chronic Kidney Disease 
The etiology of CKD has changed over the past decade Table 2 lists the primary 
causes of ESRD between 1997 and 2006 
Table 2 
Percent Distribution of Incident ESRD Patients in Canada by Primary Cause of Renal 
Failure 1997-2006 
Diagnosis 
Diabetes 
Vascular 
PCKD 
GN 
Pyelonephritis 
Drug induced 
Unknown 
Other 
1997 
28 9 
178 
47 
55 
47 
16 
15 8 
10 9 
1998 
29 9 
195 
43 
16 0 
47 
1 7 
13 1 
10 8 
1999 
314 
20 5 
45 
153 
45 
13 
12 5 
99 
2000 
32 1 
20 3 
47 
13 7 
40 
1 8 
118 
11 5 
2001 
33 8 
192 
39 
13 3 
41 
21 
14 0 
97 
2002 
33 8 
184 
40 
12 7 
42 
21 
14 7 
10 1 
2003 
34 2 
186 
42 
12 9 
43 
20 
14 3 
95 
2004 
34 3 
184 
43 
13 1 
45 
1 8 
13 5 
10 1 
2005 
35 0 
195 
5 1 
114 
39 
20 
12 2 
109 
2006 
34 4 
195 
8 
116 
35 
1 7 
12 9 
11 7 
Adapted from Canadian Institute for Health Information, 2008 Annual Report—Treatment of End-Stage Organ 
Failure in Canada, 1997 to 2006 (Ottawa, Ont CIHI, 2008) ISBN 978-1-55465-391-1 (PDF) Note PCKD-
Polycystic Kidney Disease, GN- Glomerulonephritis 
Diabetes has remained the most prevalent cause of ESRD in Canada Diabetic 
nephropathy was the leading cause of renal failure between 1997 and 2006 in Canada, with 
incidence rates increasing to 34 4% of all new cases of renal failure in 2006 (Canadian 
Institute for Health Information, 2008) The global increase in the incidence and prevalence 
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of diabetes over the last twenty years has had a direct impact on the incidence of CKD and 
the need for dialysis treatment 
The second most common cause of ESRD is hypertensive/vascular disease In the 
United States between 1990 and 2001, the incidence of ESRD related to hypertension has 
increased by almost 50% (Eustace & Coresh, 2005) Since 1997, the incident rates of ESRD 
related to vascular disease have increased minimally in Canada from 17 8 % to 19 5 % 
These differences may be related to better treatments of hypertension in the last decade, 
therefore reducing the rate of renal disease related to vascular disease Hypertension is both 
a cause and consequence of ESRD Over 75% of CKD patients develop hypertension related 
to an inability of the kidney to regulate blood pressure (Levin et al , 2008) 
Other causes of CKD are glomerulonephritis (GN), polycystic kidney disease 
(PCKD) and obstructive uropathy (Pereira, Sayegh & Blake, 2005) Glomerulonephritis is 
the third leading cause of ESRD in Canada Within the last decade, there have been 
decreasing trends in the incidence of glomerulonephritis and pyelonephritis and nearly 
unchanged rates of PCKD in Canada (Canadian Institute for Health Information, 2008) 
Hemodialysis Treatment for ESRD 
Hemodialysis is derived from two terms, hemo meaning "blood" and dialysis 
meaning "to pass through" Blood is passed through a semi-permeable membrane by 
diffusion to separate toxic wastes, excess water and electrolytes from the blood (American 
Nephrology Nurses' Association, 2007b) The overall treatment goal of hemodialysis is to 
correct electrolyte and fluid imbalance in addition to removing uremic toxins (Levin et al , 
2008), completed by the continuous flow of blood across a dialyzer membrane (Yeun & 
Depner, 2005) A concurrent passage of dialysate solution along the opposite side of the 
semi-permeable membrane provides an environment in which loss of solutes can occur via 
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diffusion (Nesrallah, Blake, & Mendelssohn, 2005) If these goals of dialysis are met, the 
patient may have improved survival by reducing the effects of uremia and its complications 
Hemodialysis is the most common form of renal replacement therapy available to 
those patients with stage five CKD (American Nephrology Nurses' Association, 2007b) 
Conventional hemodialysis consists of 3 to 4-hour treatments, three times a week (Levin et 
al , 2008) In Canada, 47 7% of all hemodialysis patients are provided treatment in a hospital 
setting (Canadian Institute of Health Information, 2008) In 2005, 57 3 % of hemodialysis 
patients in B C received treatment in a hospital, while 36% received treatment in a 
community dialysis unit, with the remainder being dialyzed at home (Canadian Institute for 
Health Information) 
Nationally, the demand for renal services, in particular RRT, is increasing each year 
There were estimated 33,832 ESRD patients in Canada in 2006, which corresponds to an 
increase of 69 7% since 1997 (Canadian Institute for Health Information, 2008) In Canada, 
the incidence of ESRD and those requiring RRT among patients 75 years and older has more 
than doubled from 1996 to 2005 (Canadian Institute for Health Information) In British 
Columbia, the increase in the number of hemodialysis patients is considerable In 1996, there 
were 747 hemodialysis patients, while in 2005 there were 1812 hemodialysis patients 
(Canadian Institute for Health Information) These trends indicate the growing need for RRT 
in addition to the provision of efficient and fiscally responsible resource allocation of renal 
services within the health care system 
The outcome of patients on dialysis remains poor The one year survival rate of 
hemodialysis patients in Canada for 2004 was 81 7% (Canadian Institute for Health 
Information, 2008) In 2008, the one year survival rate of hemodialysis patients in British 
Columbia was 83% (British Columbia Provincial Renal Agency, 2008) The three year 
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survival rate for hemodialysis patients in Canada was 57 7% in 2003 (Canadian Institute for 
Health Information) Between 1996 and 2005, the five year survival rate for Canadian 
patients on dialysis was approximately 40% (Canadian Institute for Health Information) 
The overall five year survival rate of hemodialysis patients in Canada shows 
differences in ethnicity Patients of Black and Asian origin showed an unadjusted five year 
survival rate of 61 7% and 55 6% respectively Patients of Aboriginal and Caucasian origin 
had the lowest survival rates of 42 5% and 36 3% respectively (Canadian Institute for Health 
Information, 2008) Prevalence of ESRD among Aboriginals in Canada is 58 4% higher than 
in non-aboriginals (Canadian Institute for Health Information) 
Regional Settings 
This study compared two British Columbia regional hemodialysis programs 
consisting of the Northern Renal Program (NRP) and the Kelowna Renal Program (KRP) 
The NRP services all renal patients located within the Northern Health (NH) The KRP 
serves all patients within the Okanagan Health Service Delivery Area (OHSDA) 
This section will provide a comparison of demographics in a health region (NH) and a 
sub region of Interior Health (IH) identified as the OHSDA NH provides health care to 
7 5% of the population of British Columbia (BC) encompassing a geographical area of 66 7% 
of BC (BC Stats, 2007a) The KRP provides renal care to the OHSDA, which serves over 
3 5% of BC's population covering 3 3% of the area of BC (BC Stats, 2007b) A comparison 
of age, ethnicity, family income and aboriginal descent between the two health jurisdictions 
indicate some differences for these variables between these communities 
The Northern Health (NH) has a younger population than the Okanagan Health 
Service Delivery Area (OHSDA) in all age categories (Figure 1) The OHSDA has an aging 
population with 19 7 % above the age of 65 years compared to 9 6% in NH region (BC Stats, 
6 
2007 a,b) NH has a higher South Asian and Filipino population in comparison to the 
OHSDA (Figure 2) At 15 6% (BC Stats), NH also has the highest rate of aboriginal persons 
living in the region compared to the OHSDA and all other BC health authorities (Figure 3) 
The OHSDA has 69 2% of its population falling within the $20,000-$79,999 income bracket 
in contrast to NH at 58% (BC Stats) In the NH region, 29 1% of its population has a family 
income bracket over $80,000 which is higher than the OHSDA at 19 9% (Figure 4) 
60 
50 
40 
Percent Distribution 
of Region 30 p- jjj - N H 
20 LJB • I •. - OHSDA 
10 
0 t • 
OUyears 18-24years 25 64years 65+years 
Age Distribution 
Figure 1 Comparison of age distribution in Northern Health and the Okanagan Health Service 
Delivery Area (BC Stats, 2007a) 
Percent Distribution -, ,-
of Region 
:m.-nL 
I NH OHSDA 
Single Chinese South Filipino Japanese Other 
origins Asian 
Ethnic origin 
Figure 2 Comparison of population ethnic origins Northern Health and the Okanagan Health Service 
Delivery Area (BC Stats, 2007a) Note Single origins-indicates a single ethnic origin other than 
ethnicity displayed on figure, e g Canadian, English, French, First Nations, other European 
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Figure 3 A comparison of the aboriginal populations in BC (BC Stats, 2007a) 
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Figure 4 A comparison of the income distribution between Northern Health and the Okanagan 
Health Service Delivery Area (BC Stats, 2007a) 
The differences between the region (NH) and the subregion (OHSDA) may have 
affected the outcomes of this study As the OHSDA has an aging population, the rates of 
hemodialysis patients within this age range were higher than NH The higher rates of 
Aboriginal persons in NH corresponded to higher rates of hemodialysis patients within the 
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NRP When examining the income distribution of both regions, no conclusions were drawn 
as to the effect on the hemodialysis population in this study 
Current Trends in the Management of Renal Anemia in ESRD 
Significance of Study 
Nephrology is a specialty in which health professionals work together in a system of 
interdependent roles to provide patient care At times, these roles will change based on 
organizational change or changes in the protocols or the structure of decision-making that 
directly meets patient needs (Sidani & Braden, 1998) Change in nursing practice has always 
been a part of the nephrology nursing As early as the 1960's, as technology in nephrology 
progressed, nephrology nurses embraced more responsibilities and autonomy with dialysis 
treatments (Fulton & Cameron, 1989) Often these changes were due to limited financial and 
human resources in the health care system Based on the current trend of increasing 
prevalence of ESRD, a shortage of nephrologists is evident in the health care system 
(American Nephrology Nurses Association, 2007a) Nephrology nurses are increasingly 
working to full scope of practice as clinical decision support tools are utilized 
Successful management of anemia through implementation of clinical practice 
guidelines can greatly improve patient outcomes (National Kidney Foundation, 2007) 
Although clinical practice guidelines may have been used prior to the anemia protocol 
implementation, the patient outcomes could not be attributed to a nurse sensitive intervention 
since the care was physician-driven and dependent For this study, Sidani's (1998) Nursing 
Role Effectiveness Model (NREM) was used as the framework to delineate the relationship 
between structure, process and outcomes in a specific nephrology nursing context This 
model frames the context of the nurse changing from a dependent role to an independent role 
in renal anemia management 
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Outcomes are an essential aspect of evaluating the contributions of a profession 
Many researchers describe a link between outcomes and interventions in the health care 
system (Donabedian, 1985, Doran, 2003, Newell, 1996, Sidani & Braden, 1998) It can be 
challenging to identify appropriate outcomes that result primarily from nursing care, but this 
is a necessary aspect of professional accountability and high quality patient care (Doran, 
2003, Frauman & Gilman, 2001) Nurse sensitive outcomes are those outcomes which can 
be directly affected or influenced by nursing care (Frauman & Gilman, 2001) With financial 
restraints and limited nursing resources, it is imperative that nurses show that the care 
resulting from their actions leads to positive patient outcomes 
Evaluation of nephrology nursing interventions is commonly measured by 
physiological patient outcomes Patient outcomes such as the adequacy of dialysis, blood 
pressure, fluid status, pulse and respiratory rate are based on nurses' assessment and 
intervention before and during a hemodialysis run (Burrows-Hudson & Prowant, 2005, 
Frauman & Gilman, 2001) A measureable patient outcome for anemia management as an 
aspect of nephrology nursing care is achieved by maintaining target hemoglobin (Hgb) levels 
(Burrows-Hudson & Prowant, 2005) Appropriate assessment, decision-making and nursing 
interventions in anemia management produce physiological patient outcomes that can be 
considered nurse sensitive 
Hemoglobin is the best indicator anemia management Nurses can keep Hgb levels 
stable through the use of an algorithm Consequently, Hgb levels can be seen as a nurse 
sensitive outcome It is essential that nurse sensitive measures demonstrate how nursing 
actions influence patient outcomes 
The goal of renal anemia management is to provide Hgb levels within an acceptable 
target range Evidence shows that effective renal anemia management takes into 
10 
consideration the interdependent relationship between iron status, intravenous iron use, 
erythropoietic stimulating agent (ESA) use and Hgb These factors, properly managed are 
associated with reduced mortality and hospitalization among hemodialysis patients (Easom, 
2006, Elliott, Pham, & Macdougall, 2008, Pisoni et al , 2004) Appropriate renal anemia 
management requires evaluation of iron status and ESA dosing to improve patient outcomes 
The use of decision support tools, such as algorithms, can assist nurses to care for the 
complex patient A decision-making tool is an evidence-based document used by nurses to 
guide the assessment, diagnosis and treatment of specific client clinical issues (College of 
Registered Nurses of British Columbia, 2008) These tools can support nurses as they 
assume increasingly independent practice in chronic disease management and reduce 
variation in client care related to individual practitioner practices (Dickerson, Sackett, Jones, 
& Brewer, 2001) The goal of using decision support tools is the achievement of positive 
patient outcomes in an efficient, cost effective and continuous manner 
Algorithms can be based on guidelines as outlined by the specialty and provide 
guidance in decision-making They are not a replacement for clinical judgment Algorithms 
or protocols can present evidence-based guidelines in visual form and enable nurses to 
outline aspects of disease management in order to make decisions about assessment, 
treatment and evaluation of care (Dickerson et al , 2001) 
Since 2006, algorithms in anemia management for hemodialysis patients have been 
mandated as standard practice in British Columbia (BC) by the British Columbia Provincial 
Renal Agency (BCPRA) The BC Medical Advisory Committee recommends that all BC 
Health Authority Renal Programs use algorithms for efficient use of erythropoietic 
stimulating agents and of nephrologists' time (British Columbia Provincial Renal Agency, 
2007) Each health authority in British Columbia has the autonomy to develop an anemia 
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management protocol using the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (KDOQI) guidelines (British Columbia Provincial Renal Agency) The 
anemia management algorithm used in the NRP is based on evidence for managing renal 
anemia as outlined in the (KDOQI) practice guidelines (National Kidney Foundation, 2006) 
At the time of the study, the KRP used the KDOQI guidelines for renal anemia 
management based upon a traditional physician-driven approach A traditional physician-
dnven approach consisted of monthly rounds with a review of patient blood work A charge 
nurse was present at rounds to provide blood work results and discuss each patient 
Adjustment of erythropoietin and intravenous iron doses was completed during rounds Any 
critical lab values were addressed urgently as necessary Table 3 outlines the differences 
between a physician-driven approach to anemia management and a nurse-driven protocol 
approach 
Table 3 
Differences of Anemia Management Practice in Physician-driven and Nurse-driven Protocol 
Approaches 
Anemia management practice Physician-driven approach Nurse-driven protocol 
approach 
Responsible for assessment, Nephrologist Hemodialysis nurses 
monitoring and evaluation of 
anemia blood work (Hgb, 
TSAT, Ferritin levels) 
Procedure for adjustment of Nephrologist adjusts Hemodialysis nurses adjust 
erythropoietin stimulating medications during monthly medications using step-wise 
agents and intravenous iron rounds and urgently as instructions outlined in 
doses needed RAMP when lab work results 
are available 
Evaluation of effectiveness of Nephrologist evaluates Hemodialysis nurses provide 
treatments treatment during monthly ongoing evaluation of 
rounds treatments using instructions 
in RAMP 
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Within the NRP, the introduction of a renal anemia management protocol (RAMP) 
(Appendix A) resulted in a change in the role of the registered nurse in the care of the 
hemodialysis patient This change encompassed greater assessment, monitoring and 
decision-making within the scope of the registered nurse Anemia management has 
traditionally been the physician's role with minimal nurse input or action 
The RAMP transfers anemia management of hemodialysis patients to nurses upon 
order of the nephrologist Based on general RAMP guidelines, all patients have monthly lab 
work drawn to assess Hgb status Depending on Hgb status, the protocol provides step-wise 
instructions on how to titrate an ESA or provide iron therapy Steps for monitoring Hgb 
status are also provided in the protocol The targeted Hgb for this adult protocol is between 
110-125 g/1 Transferrin saturation level is targeted between 20% and 50% The ferritin 
levels are recommended between 200-500 ug/L These targets were agreed upon by the 
RAMP committee based on the KDOQI guidelines at the time of printing This protocol 
enables the nephrology nurse to treat anemia in a timely manner 
Research Context 
This study compared patient outcomes in two settings Patients from the KRP served 
as a control group using data between November 2005 and November 2006 when an anemia 
protocol was not in use The NRP was identified as the protocol group during a time period 
that the protocol was in use from October 2007 to October 2008 The difference in time 
periods is due to the introduction of an anemia protocol in one of the community units linked 
to the KRP after December 2006 The KRP is considered to be a control population based on 
its comparable size in numbers of patients and the inclusion of two community units located 
in Vernon and Rutland, BC The KRP also has an organizational structure similar to the 
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NRP based on the British Columbia Provincial Renal Agency (BCPRA) renal program 
guidelines (British Columbia Provincial Renal Agency, 2004) 
The NRP provides renal services for all residents of Northern Health in BC This 
area encompasses the Northwest, Northern Interior and Northeast health service delivery 
areas in the province The primary renal management centre is located at the University 
Hospital of Northern British Columbia (UHNBC) in Prince George, BC Hemodialysis 
services consist of an in-centre hemodialysis unit at UHNBC and interdependent community 
dialysis units located at Terrace and Fort St John The UHNBC hemodialysis unit serves as 
the regional base for both community units In October 2007, there were 73 in-centre 
hemodialysis patients, 17 Fort St John community patients, and 14 Terrace community 
patients in the program (British Columbia Provincial Agency, 2008) for a total of 104 
patients with approximately 60 patients on the RAMP 
The KRP provided renal services to all hemodialysis patients in the OHSDA The 
primary regional unit is in Kelowna General Hospital and two interdependent community 
units are located in Rutland and Vernon, BC In October 2005, there were approximately 38 
Kelowna in-centre patients, 19 patients in the Rutland unit and 25 patients in the Vernon unit 
At this geographic location, 82 patients were not on an anemia protocol 
Through a retrospective, non-equivalent, group design, this study looked at the impact 
of implementing a decision support tool within the NRP hemodialysis population The 
outcome variables evaluated included Hgb levels, transferrin saturation levels, ferritin levels 
in addition to intravenous iron and ESA use An exploration of the relationship between 
interventions and outcomes in two comparable hemodialysis populations occurred 
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Research Questions 
The introduction of the RAMP in the NRP arose from the need to better manage Hgb 
levels for patients with renal anemia The trend of exceeding Hgb targets was of concern for 
patient safety and cost effective use of ESA's The goal of this study was to provide 
evidence concerning whether the use of a nurse-driven decision making tool in the 
hemodialysis setting could result in effective and safe patient outcomes compared to 
traditional physician-driven approaches to anemia management There are two research 
questions that were explored in this study 
1) In the hemodialysis population, does using a nurse-driven anemia management protocol 
enable patients to maintain target Hgb levels as effectively as a non-protocol based 
physician-driven approach7 
2) Is there a relationship between anemia management practice approach and Hgb levels, iron 
levels, intravenous iron use and erythropoietin use in the hemodialysis setting7 
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CHAPTER 2 
Review of Literature 
The treatment of renal anemia requires an understanding of the impact ESAs and 
intravenous iron have on patient outcomes such as target Hgb levels and iron levels in the 
body The use of decision making tools such as algorithms or protocols, directs the nurse 
with steps to treat, monitor and evaluate renal anemia management Using the evaluation 
framework of the Nursing Role Effectiveness model (NREM), this study will apply its 
concepts to nurse-driven renal anemia management 
Renal Anemia 
Anemia is a condition marked by a reduction of red blood cells in the body (National 
Institutes of Health, 2008) Although there are many contributors to anemia, renal anemia is 
unique to end stage renal patients as it directly relates to erythropoietin deficiency in the 
body Erythropoietin is vital to the development of red blood cells 
Erythropoiesis is a physiologic process of maintaining oxygen levels in the body 
through the actions of erythropoietin (Elliott et a l , 2008) The release of erythropoietin 
directly corresponds to oxygen levels in the body (Elliott et al) Hypoxia, which triggers a 
renal oxygen sensor in the kidney, leads to an increase in the production of erythropoietin 
resulting in the development of red blood cells (Hodges, Rainey, Lappin, & Maxwell, 2007, 
National Institutes of Health, 2008, Tranter, Martinez, & Rayment, 2006) By increasing the 
concentration of red blood cells and Hgb, the oxygen carrying capacity is improved 
Decreased erythropoietin (EPO) production in chronic kidney disease is the primary 
cause of renal anemia (Dalton & Schmidt, 2008, Drueke et al, 2006, Levin, 2007, Singh, et 
al, 2006) Renal anemia is a common complication of kidney failure (Collins et al , 2005, 
National Kidney Foundation, 2007, Singh & Hertello, 2005, Stnppoh, Navaneethan, & 
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Craig, 2006) At Stage 5 CKD (Table 1), also known as ESRD, 60-80% of patients are 
affected by renal anemia (Hsu, Mcculloch, & Curhan, 2002) 
There are various factors which can influence the development of anemia in 
hemodialysis patients Hemodialysis patients can experience gastrointestinal bleeding, 
shortened erythrocyte survival time of 30-60% of the normal 120 days, iron deficiency and 
increased blood losses at hemodialysis runs (O'Mara, 2008, Pisoni et al , 2004) Increased 
hemolysis related to the toxic effects of uremia can also exacerbate anemia in the 
hemodialysis patient (Pruett, Johnson, & O'Keefe, 2007) 
Anemia in hemodialysis patients has significant consequences Anemia is associated 
with decreased exercise capacity, reduced cognitive function, depression, and decreased 
quality of life (Ludwig & Strasser, 2001, Painter et al , 2002, Silverberg et al, 2003) Renal 
anemia can have a negative impact on cardiac function due to vasodilation, cardiac dilation, 
increased cardiac output leading to left ventricular hypertrophy, and congestive heart failure 
(Locatelh et al , 2007, Silverberg, lama, Wexler, & Blum, 2001) Between 1996 and 2005, 
cardiac failure was the leading cause of death among end stage renal disease patients in 
Canada (Canadian Institute for Health Information, 2008) 
Treatment of anemia has the potential to improve the strength and function of muscle 
as well as improve cognitive and brain electrophysiological function due to an increase in 
peripheral oxygen supply (Mason & McMahon, 1997, McMahon et al , 2000) Effective 
anemia management is associated with lower morbidity and mortality among hemodialysis 
patients (Brattich, 2006, Pisoni et al , 2004) 
Erythropoietin and ESA Therapy 
Erythropoietin (EPO) is an amino acid hematopoietic growth factor of which 
approximately 90 % of EPO is produced by the kidneys (Drueke et al , 2006, Elliott et al , 
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2008, O'Mara, 2008) If there is damage to the kidney, its ability to produce adequate 
amounts of erythropoietin is compromised (O'Mara) Renal anemia is treated by 
supplementing reduced erythropoietin levels in the body with erythropoietic stimulating 
agents (Cody et al , 2005, Dalton & Schmidt, 2008) 
EPO acts on the bone marrow to stimulate red blood cell production The bone 
marrow manufactures red blood cells through a series of events The stem cell also known as 
the hematopoietic progenitors differentiate into burst-forming erythroid cells and then 
colony-forming erythroid cells Each colony-forming erythroid cell has erythropoietin 
receptors and is erythropoietin dependent EPO is required to attach to the erythropoeitin 
receptor on the erythroid cell to continue process of producing red blood cells The erythroid 
cell is then differentiated into erythroblasts, reticulocytes and mature erythrocytes 
respectively (Elliott et al , 2008) 
The magnitude of increase in red blood cell concentration is controlled by the length 
of time EPO concentrations are maintained and not by the EPO level itself (Elliott et al , 
2008) As a result, measuring EPO levels has little significance in renal anemia management 
The aim of renal anemia management is maintaining consistent EPO concentrations over 
time to impact Hgb levels 
The maintenance of adequate EPO levels is affected by several factors The balance 
between red blood cell production and destruction can be influenced by blood losses and 
kidney defects in oxygen sensing (Elliott, et al , 2008) Particularly in CKD, inadequate 
concentrations of erythropoietin and reduced life span of the red blood cell trigger an 
imbalance in erythropoiesis resulting in renal anemia 
Erythropoietic stimulating agents (ESA) are genetically engineered forms of the 
naturally occurring human erythropoietin hormone Epoetin alfa was the first ESA to be 
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developed and is administered 1 to 3 times per week with dosing based on weight of the 
patient, 50-100 units/kg (Duh, Werner, White, Lefebvre, & Greenberg, 2008) Epoetin beta 
is another form of ESA with similar starting doses as epoetin alfa Darbepoetin alfa is 
another form of erythropoeitin with a longer half life than epoetin alfa, taking 3 to 5 times 
longer to reach peak serum concentrations (Duh et al) Starting doses for Darbepoetin alfa 
are 0 45 ug/kg at weekly to every three week intervals (Duh et al) 
Erythropoietic stimulating agent (ESA) therapy, also known as erythropoietic 
hormone replacement therapy (EHRT), has become the first line of treatment for more than 
90% of hemodialysis patients (National Institutes of Health, 2008, Patel, Robinson, & Singh, 
2007) ESAs have changed the way renal anemia is treated and this treatment is associated 
with decreased mortality, morbidity, disease progression, cardiovascular risk, and an 
improvement in quality of life in hemodialysis patients (O'Riordan & Foley, 2000, Ritz & 
Eisenhardt, 2000) 
Prior to the use of ESAs, blood transfusions exposed the hemodialysis population to 
considerable risk Repeated blood transfusions do little to maintain Hgb at a target level and 
can cause iron overload (Bennett, 1998, Easom, 2006) Blood transfusions can also sensitize 
a patient to develop antibodies in the blood or viral infections, placing them at risk of 
unsuccessful transplant matches (Bennett) After exposure to Human Leukocyte Antigens 
(HLA) m previous blood transfusions, a patient can develop antibodies against HLA antigens 
resulting in difficulty finding a suitable transplant organ and increased risk of rejection of the 
organ (Magee, 2005) Blood transfusions can also introduce viral infections such as Hepatitis 
B, Hepatitis C, and Cytomegalovirus to the patient (Magee) Ideally, the use of ESAs can 
reduce the need for blood transfusions and can contribute to successful future transplantation 
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Erythropoietic stimulating agent dosing varies with clinical indication, practitioner 
and geographic region (Elliott et al , 2008) Results from the Dialysis Outcomes Practice 
Patterns study (DOPPS) of 12 countries demonstrate variable ESA dosing patterns worldwide 
(Pisoni et al , 2004) These differences are influenced by patient co-morbidities, 
hospitalization rates, national and regional practice guidelines, in addition to practice patterns 
(Pisoni et al) These variations account for many of the differences of patient outcomes 
worldwide 
Hyporesponse of hemodialysis patients to ESAs is identified in literature 
Hyporesponse to epoetin alfa is recognized as a potentially modifiable occurrence correlated 
to the following factors inadequate epoetin doses, blood loss, acute inflammation or 
infection, iron deficiency, poor nutritional status, and vitamin deficiency (Deziel, 2002, 
Kalanatar- Zadeh et al , 2009, National Kidney Foundation, 2006) High bone turnover 
disease as indicated by elevated serum alkaline phosphatase and parathyroid hormone levels 
has been correlated with ESA hyporesponse (Kalantar-Zadeh et al) 
Hyporesponse to epoetin alfa in hemodialysis patients is correlated with inflammation 
and malnutrition (Chawla & Knshnan, 2009) Literature shows that elevated pro 
inflammatory biomarkers such as c reactive protein (CRP) levels are present in some 
hemodialysis patients and coupled with low albumin levels, can be predictors of epoetin alfa 
hyporesponse (Breiterman-White, 2006, Deziel, 2002) Studies have demonstrated that high 
inflammatory biomarkers correlate with incidence of congestive heart failure, coronary heart 
disease, and vasculitis (van Tellingen et al, 2002) A patient with an inflammatory disorder, 
as evidenced by high ferritin levels, could require increases in epoetin alfa doses to maintain 
Hgb levels at acceptable targets (Drueke, 2001) Inflammation in diabetic hemodialysis 
patients is common as a result of the presence of atherosclerosis, proteinuria, diabetic 
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neuropathy, diabetic retinopathy, and infections (Jenq, Hsu, Huang, Chen, Lin, & Lin-Tan, 
2009) 
The use of ESAs in the United States is on the rise and this has a significant impact 
on the financial resources of renal programs There has been a dramatic rise in epoetin 
dosing between 1993 and 2005 (National Institutes of Health, 2008) In the United States, 
between 1991 and 2005, the mean monthly Hgb in dialysis patients rose 24 g/L and the 
weekly EPO doses rose threefold to over 19,000 units (National Institutes of Health) ESA's 
account for 10% of ESRD costs of all patients on hemodialysis or peritoneal dialysis 
(National Institutes of Health) 
Iron 
The most important goal of iron therapy is to support optimal erythropoiesis to allow 
target Hgb levels to be reached and maintained It is crucial that careful monitoring of iron 
status and the dosing of iron therapy take into account the uniqueness of each patient An 
essential component of anemia management is the routine monitoring of iron status (Easom, 
2006) KDOQI guidelines recommend iron status measurement every 3 months during stable 
ESA treatment (National Kidney Foundation, 2006) Regular monitoring of iron levels is a 
vital part of anemia management in the hemodialysis patient for several reasons 
It is common for hemodialysis patients undergoing ESA treatment to experience 
"functional iron deficiency" (Pruett et al , 2007, p 207) Iron deficiency is multi-factorial in 
the hemodialysis patient Iron deficiency can be due to retention of blood in the dialyzer and 
tubing as well as frequent laboratory tests (Singh & Hertello, 2005) Patients can fail to 
adequately respond to ESAs due to iron deficiency, as iron is a necessary component to 
complete the red blood cell production cycle (National Kidney Foundation, 2006) ESA 
treatment also increases erythropoiesis at rates higher than normal to support Hgb synthesis, 
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thus increasing the demand for iron faster than can be released from iron stores in the body 
(Pruett et al) Although the absorption of iron by the body increases as much as five times 
normal during erythropoietin therapy, losses from hemodialysis and blood testing may 
exceed gastrointestinal iron absorption (Fishbane, Frei & Maesaka, 1995, Skikne, Ahauwalia, 
Fergusson, Chonko, & Cook, 1998, Skikne & Cook, 1992) 
Transferrin saturation (TSAT) and ferritin levels are often used to diagnose and treat 
iron deficiency in hemodialysis patients (Singh, Coyne, Shapiro, & Rizkala, 2007) TSAT is 
a measure of iron stores available for red blood cell production corresponding to the 
circulating iron bound to transferrin (Kalantar-Zadeh et al , 1998) Greater TSAT has a 
positive association with effective anemia control (Pisoni et al , 2004) Serum ferritin is the 
amount of iron stored m the body as released by tissues (Easom, 2006, Kalantar-Zadeh, 
Rodriguez, & Humphreys, 2004) Ferritin levels alone are "an imprecise marker of iron 
status due to inflammatory factors which may interfere with synthesis and clearance of 
ferritin" (Easom, p 545) 
ESRD, hemodialysis, infections and protein energy malnutrition are factors which can 
activate the inflammatory response (Easom, 2006) Serum ferritin levels can increase during 
inflammatory disorders Inflammation iron block occurs resulting in a type of functional iron 
deficiency potentially disrupting erythropoiesis (Easom) Inflammation within the 
hemodialysis population may be as high as 40% to 60% (Kalantar-Zadeh et al , 2004) 
Elevated serum ferritin (500-2000pg/ml) should not be a marker for excessive iron but could 
be an "indication of iron plus inflammation in hemodialysis patients" (Easom, p 547) 
Nephrology nurses must use critical clinical thinking when interpreting KDOQI guidelines of 
serum ferritin of 500 p.g/ml as an upper limit for withholding intravenous (IV) iron therapy 
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(Easom) Nephrology nurses must evaluate each individual patient's response to IV iron 
based on ESA responsiveness, Hgb level, and clinical status 
Intravenous (IV) iron administration is the preferred route for hemodialysis patients 
There is a strong recommendation for treatment with intravenous iron within the 
hemodialysis setting in clinical guidelines (National Kidney Foundation, 2006) In a 
systematic review and meta-analyses of hemoglobin outcomes in hemodialysis patients using 
oral iron versus intravenous iron, the better hemoglobin response was with the patients 
treated with intravenous iron (Rozen-Zvi et al , 2008) Three randomized control trials 
comparing IV iron with oral iron administration in hemodialysis patients showed that the use 
of IV iron resulted in greater Hgb levels and reduced the need for higher ESA doses when 
compared with patients using oral iron (Fishbane, Frei, & Maesaka, 1995, Fudin, Jaichenko, 
Shostak, Bennett, Gotloib, 1998, Macdougall et al , 1996) 
In the past, iron overload was a legitimate concern in the care of hemodialysis 
patients Blood transfusions were common in hemodialysis patients and resulted in up to 6 g 
of parenteral iron per year (Easom, 2006) Iron, in the absence of erythropoiesis proved to be 
detrimental to the patient The greater use of ESAs coupled with the reduced need for blood 
transfusions has resulted in a reduced risk of iron overload in hemodialysis patients (Easom) 
It is unlikely that iron overload could occur with the use of appropriate intravenous iron 
dosing 
There are three forms of intravenous iron used in the RAMP (Appendix A) Iron 
dextran, iron sucrose and iron gluconate are parenteral forms of iron that are funded under 
the British Columbia Provincial Renal Medication Program The decision for which form to 
use is dependent on physician choice, patient tolerability and the evidence related to safety of 
each form 
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Iron dextran was the only form of parenteral iron available in the United States until 
1999 It has proven efficacy but its safety has been questionable (Faich & Strobos, 1999) It 
has been reported that approximately 0 7% of iron dextran use in hemodialysis patients has 
resulted in life threatening anaphylactic reactions (Fishbane, Ungureanu, Maesaka, Kaupke, 
Lim, & Wish, 1996) Between 1976 and 1999, there were 30 deaths attributed to iron 
dextran use (Faich & Strobos, 1999) In a meta-analysis of studies of iron dextran use found 
drug intolerance rates of approximately 2 47% and anaphylaxis rates of 0 61 %, p< 0 0001 
(Michael et al , 2002) It has been speculated that the high molecular weight dextran 
molecule rather than the iron itself induces anaphylaxis or contributes to adverse effects 
(Faich & Strobos, 1999, Michael et al , 2002, Sengolge, Horl, & Sunder-Plassman, 2005) 
Iron sucrose and iron gluconate (Ferrlecit) are increasingly being used in the hemodialysis 
setting due to the risk of serious adverse drug reactions related to iron dextran 
Iron sucrose therapy is a safe alternative to iron dextran use In a summary of four 
prospective studies of 130 iron dextran or iron gluconate sensitive patients, no serious 
adverse events (anaphylaxis or death) occurred related to iron sucrose therapy in these same 
patients Fourteen non-serious drug related adverse events such as diarrhea, hypotension, 
nausea, vomiting and constipation occurred in 8 patients (Charytan, Schwenk, Al-Saloum, & 
Spinowitz, 2004) 
Sodium ferric gluconate complex (iron gluconate or Ferrlecit) is a form of 
intravenous iron in which there is significantly less allergic and anaphylactic reactions 
occurring in comparison to iron dextran In a randomized controlled double blinded study of 
2534 hemodialysis patients, there was a rate of immediate type of reaction of 0 04% (Michael 
et al , 2002) This indicates a statistically significant lower rate of anaphylaxis when 
compared to 0 61% in iron dextran use,/?=0 0001 (Michael et al , 2002) 
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Target Hemoglobin Levels 
Considering the impact of renal anemia on hemodialysis patients, several studies have 
looked at treatment and safety issues surrounding the use of ESAs For many years, the 
assumption in the nephrology community was that normalized Hgb levels presented positive 
outcomes for hemodialysis patients As a result, many studies were organized around this 
hypothesis 
A systematic review of Hgb targets in renal anemia found that many studies 
hypothesized that higher Hgb levels were positively associated with improved survival The 
results indicate otherwise Of twenty-two randomized control trials involving 3707 patients, 
it was found that Hgb > 130 g/L was not associated with decreased risk of mortality when 
compared to Hgb levels of 120 g/L Lower Hgb targets of < 100 g/L resulted in increased 
risk of seizure (RR 5 25, 95% CI 1 13-24 34) and a decreased risk of hypertensive episodes 
(RR 0 05, 95% CI 0 33-0 76, Strippoli et al , 2006, p i ) The results regarding quality of life 
and higher Hgb values were inconclusive due to non-validated scales of assessment and 
"presentation of individual positive results instead of a generalized assessment useful for 
analysis" (Strippoli et al , p 8) The limitations of this review include the limited number of 
RCT's available, the small sample sizes in RCTs and the lack of primary end points at the 
patient level (Strippoli et al) 
A meta-analysis of nine randomized controlled trials of various target Hgb of 5143 
patients provided similar results (Phrommintikul, Haas, Elsik, & Krum, 2007) Higher Hgb 
targets demonstrated an increase of 20% in mortality, 30% in arteriovenous access 
thrombosis and 30% of poorly controlled blood pressure In this study, higher Hgb target 
levels were considered 120-160 g/L A sub-group of dialysis patients showed a relative risk 
of 1 11 (95 % CI 0 94-1 31, p=0 22) in the higher target Hgb group compared to the lower 
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Hgb group In addition, the risk of poorly controlled blood pressure was significantly higher 
in the high Hgb group than the low Hgb group (RR 1 27, 95% CI 1 08-1 50,p=0 004, 
Phrommintikul et al) 
In 2006, two studies were published that resulted in the amendment of the National 
Kidney Foundation guidelines indicating an upper Hgb limit of 130 g/L The Correction of 
Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial studied 1432 patients with 
chronic kidney disease who were randomly assigned to receive epoetin targeted to achieve 
Hgb levels of 135 g/L or 113 g/L The primary end point was death, myocardial infarction, 
hospitalization related to congestive heart disease or stroke The results indicated that the 
higher Hgb group had a higher incidence of the primary end point and the trial was 
terminated early A target Hgb of 135g/L was associated with increased risk and no 
improvement in quality of life (Singh et al, 2006) Based on this evidence, the authors of the 
CHOIR study suggested that a target Hgb range of 110-120 g/L is based on lower risks and 
lower treatment costs 
The Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin beta 
(CREATE) study randomly assigned 603 patients with Stage 3 or 4 chronic kidney disease to 
two groups with target Hgb levels of 130-150 g/L or 105-115 g/L The primary endpoint was 
eight cardiovascular events including sudden death, myocardial infarction, acute health 
failure, stroke, angina or cardiac arrhythmias with twenty four hour hospitalization, and 
peripheral vascular disease complications After three years, the CREATE researchers found 
that there was no significant difference between the two groups with regard to adverse 
events They concluded that normalization of Hgb in CKD anemic patients does not reduce 
the risk of cardiovascular events The CREATE study did find a slight increase in quality of 
life measurement in higher Hgb group (Drueke et al , 2006) 
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Both studies (Drueke et al, 2006, Singh et al , 2006) found that the event rates were 
higher among the participants that responded poorly to ESAs Some critics argued that the 
difference in event rates was most likely due to the high burden of disease among these poor 
responders as opposed to the variation of Hgb within the target range (Demirjian & Nurko, 
2008, Greene et al , 2005) Other critics argued that a slight increase in quality of life is of 
significance to the patient and this should be considered on an individual basis (Muirhead, 
2007) The conclusions from these studies suggest that Hgb > 130 g/L is not recommended 
due to increased risks of cardiovascular adverse effects The studies also indicated that there 
are positive effects to quality of life when normalization of Hgb occurs 
A recent study on Hgb level variability did not find increased mortality among the 
above target range or even the higher end of target range (Gilbertson et al, 2008) Because 
this was an observational trial, its results have potential for more biases as compared to the 
CREATE and CHOIR randomized control trials and exert less influence over current 
treatment guidelines 
Other studies have provided inconsistent results as they pertain to safe target Hgb 
ranges The Anemia in Chronic Heart Failure Outcomes and Resources utilization study 
(ANCHOR) found that the ESRD population with chronic heart failure with Hgb >170 g/L 
levels were at the highest risk of death, and the risk was reduced as the Hgb decreased to 130 
g/L level (Go et al , 2006) A randomized controlled trial of 157 hemodialysis patients 
within a group of predialysis and peritoneal dialysis patients demonstrated that Hgb levels of 
135-160 g/L improved quality of life as measured by decrease in fatigue, depression and 
frustration The incidence of thrombovascular events and vascular access thrombosis in 
hemodialysis patients did not differ between the lower and higher target Hgb (Furuland et al , 
2003) A randomized, double blind study of the effect of normalized Hgb targets (Hgb 135-
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145 g/L) on hemodialysis patients without symptomatic heart disease found that it has no 
beneficial effect on cardiac structure as evidenced by left ventricular volume index (Parfrey 
et al , 2005) 
KDOQI guidelines from 2006 conclude that a Hgb lower limit of 110 g/L and an 
upper limit not > 130 g/L are the most efficacious in terms of disease management (National 
Kidney Foundation, 2006, p S33) On the basis of the CREATE and CHOIR studies, 
maintenance of Hgb levels >130g/L appears to require more epoetin, increasing costs to 
health care while placing patients at significant risk of adverse cardiovascular events 
(Steinbrook, 2006) Based on the wording of this guideline, no upper limit was determined 
except for avoiding Hgb >130 g/L This was considered an opinion-based guideline and has 
since been amended to an evidence-based guideline Current evidence supports a Hgb target 
range of 110g/L-120 g/L (National Kidney Foundation, 2007) 
Normalization of Hgb levels is a complex issue in hemodialysis patients As reported 
by the United States Renal Data System Annual Report, 42% of patients reaching Hgb > 140 
g/L, achieve this level within six months of reaching the target level of 110 g/L (National 
Institutes of Health, 2008) Lack of attention to the higher target Hgb levels may lead to 
overuse of ESAs, contributing to overshooting targets (Collins, Ebben, & Gilbertson, 2007) 
Indeed, overshooting the target Hgb level was 3 to 4 times more common in 2008 than it was 
in 1997 (Kapoian, 2008) Higher ESA doses is associated with decreased survival by 
reflecting resistance to ESA treatment within coexisting inflammation and malnutrition 
issues (Kalantar-Zadeh, Kopple, Block, & Humphreys, 2001, Locatelh et al , 2006) 
Just as higher Hgb levels increase health risks for the hemodialysis patient, lower Hgb 
levels expose the patient to a greater risk In a study of 12 countries and dialysis outcomes, 
23-29% of hemodialysis patients were below 110 g/L in Sweden, the United States, Belgium 
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and Canada (Pisoni et al , 2004) Hemodialysis patients with lower Hgb levels were 
potentially at the highest risk of mortality (Locatelh, Conte, & Marcelh, 1998) 
Hyporesponsiveness to ESAs creates a challenge to maintain the minimum Hgb target 
level One study indicated that 75% of ESA hyporesponsive patients with a non-functioning 
arteriovenous graft had evidence of a bacterial infection without symptoms The only 
evidence of infection was higher ferritin levels with low Hgb levels, suggesting inflammation 
or infection can greatly influence anemia management (Nassar, Fishbane & Ayus, 2002) 
Additional studies have addressed the challenge of maintaining Hgb levels within a 
narrow target range, indicating large variability in individual patient results (Berns et al , 
2003, Lacson, Ofsthun, & Lazarus, 2003) "Achievement of Hgb within this target range is 
prone to fluctuation" (National Kidney Foundation, 2007, p 503), and is a common 
phenomenon in hemodialysis patients (Walker & Pussell, 2007) It has been reported that 
90% of hemodialysis patients have cyclical Hgb results averaging 10 3 weeks and 25 g/L in 
range (Fishbane & Berns, 2005) The variability of Hgb levels observed in clinical practice 
indicates that 95% of hemodialysis patients using ESAs would obtain a Hgb interval range as 
high as 56 g/L (using a normal curve) (Berns et al , 2003) Hemoglobin variability can be 
influenced by the appropriateness of physician orders for ESA dose change, biological 
diversity within a population, unique patient responsiveness to ESAs, hemodilution related to 
fluid overload, adequacy of iron stores, bleeding, and inflammatory responses (Collins et al , 
2005) 
According to one study of Hgb variability, a typical hemodialysis patient can be 
expected to have 42% of 3 month rolling average Hgb values outside of the 110-120 g/L 
range (Lacson, Ofsthun, & Lazarus, 2003) Variability in results among hemodialysis 
patients will present transient Hgb levels >130 g/L and a temporary spike does not constitute 
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a safety concern when appropriate adjustments are made to ESAs (National Kidney 
Foundation, 2006) Related to intrapatient Hgb variability, Lacson et al (2003) suggest that 
a wider target range will reduce the likelihood of staff responding aggressively to Hgb levels 
and decreasing Hgb fluctuations 
Variability of Hgb levels can be associated with increased mortality A one year 
retrospective study of 159,720 hemodialysis patients showed the degree of Hgb variability, 
low and highly variable levels were associated with increased risk of death (Gilbertson et al , 
2008) Patients consistently within target hemoglobin levels, as well as those persistently 
over target, had lower mortality rates (Gilbertson et al) These results speak to the necessity 
of ensuring best outcomes for patients by maintaining Hgb levels within acceptable range 
Examining Hgb results require monitoring of longitudinal trends to prevent sudden 
reaction to isolated Hgb values, taking into account changes m a patient's condition such as 
infection or hospitalization (Breiterman-White, 2003) A single Hgb level often reflects a 
range of ESA doses over a period of time (Locatelli, Del Vecchio, & Pozzoni, 2007, National 
Kidney Foundation, 2007) Withholding ESAs for a Hgb level greater than target range 
contributes to unpredictable and variable Hgb levels downward Incrementally decreasing 
EPO doses provides effective clinical results as opposed to holding doses which can result in 
plummeting Hgb levels (Breiterman-White) 
There is an association between Hgb levels and hospitalization In a prospective 
observational study of 11,041 hemodialysis patients from 7 countries, results concluded that 
the risk of hospitalization decreased 9-55% over 5 years in patients with Hgb 110-120 g/L 
(Pisoni et al, 2004) In a study of U S hemodialysis patients treated with ESAs, Hgb levels 
dropped 5 3 g/L within 30 days of hospitalization as compared to 3 months prior and this was 
statistically significant (p< 0 001, Pisoni et al) It is evident that patients who are 
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hospitalized can experience more pronounced anemia Pisoni et al demonstrated that 
mortality and hospitalization risks decreased by 5-6% for every 10 g/L increase in Hgb level 
up to target range 
Clinical Decision-making 
Clinical decision-making is an essential skill that impacts the nurse, patient and 
institution The quality of clinical decision-making determines the delivery of nursing care 
and the quality of patient outcomes (Ames, 2006) Each nurse brings unique knowledge to a 
clinical problem and this plays a role in how a problem is interpreted and which clinical 
issues will be attended to (Jones, 1988 as cited in Bakahs & Watson, 2005) Clinical 
decision-making can also impact an institution The quality of a nurse's decision-making 
influences the outcome for the patient which can financially impact an institution (Ames) 
Because of the diversity of nursing, education, knowledge and experience in any health care 
institution, standardization of patient care can assist in providing better patient outcomes 
The role of the registered nurse (RN) has become more complex as changes to the 
health care system demand increased responsibilities for the care of the patient An emphasis 
on cost-effectiveness in conjunction with increased disease chromcity requires highly 
qualified, accountable individuals who accept responsibility for decision-making about 
patient care (Mrayan, 2003) A strategy to control costs while maintaining quality of care is 
to expand the scope of activities of the nurse Transferring medical management of a specific 
clinical issue creates an environment where nursing has greater responsibility and 
accountability for patient care (College of Registered Nurses of British Columbia, 2008) 
The College of Registered Nurses of British Columbia (CRNBC) strongly encourages 
employers to develop decision-making tools to assist nurses in their clinical practice as 
responsibilities and activities expand In BC, health care employers are responsible for the 
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development and initiation of any clinically-based client decision making tool that nurses use 
(CRNBC, 2008) 
Decision-Making Tools 
Clinical protocols are based on a standardized approach to practice and derive its 
origins from algorithms (Ilott, Booth, & Patterson, 2010) A clinical algorithm is a set of 
logical, sequential steps shown as a decision tree which directs patient care (Gerdtz & 
Bucknall, 1999, Miller, York, & Ryan, 2005) An algorithm in the clinical setting is linear in 
approach to clinical problem solving, displaying major decision points in disease 
management and strategies of action (Department of Veteran Affairs, 2002, Schwartz & 
Griffin, 1986) Using a specific, logical approach to clinical problem solving is essential to 
decision-making and can assist in the assessment of the patient (Department of Veteran 
Affairs, 2002) 
Algorithms and/or protocols which incorporate clinical practice guidelines provide a 
framework for evidence-based care within a specialty Within the nephrology specialty, the 
KDOQI clinical practice guidelines and recommendations are the standard guidelines for all 
stages of chronic kidney disease (National Kidney Foundation, 2006) Algorithms within a 
specialty cover the scope of a guideline to provide a summary of appropriate management 
decisions and strategies to address specific patient issues (Hadorn, 1994) Ideally, an 
algorithm is the translation of research into functional interventions, using a problem solving 
orientation to create steps grounded in evidence-based principles and practice (Miller et al , 
2005) 
The advantages of clinical algorithm use in practice relates to its impact on patients, 
clinical practice, and institutions Algorithms can assist nurses to identify when testing is 
unwarranted and as a result provides more efficient patient care (Hadorn, 1994) Algorithm 
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use in clinical practice can improve patient safety related to standardization of care regardless 
of size or geographical remoteness of practice site (McDonald, 2007) Reducing variations 
by standardizing clinical practice is effective in minimizing the probability of error in 
judgment (Kohn, Corrigan, & Donaldson, 1999), thus placing the nurse at lower professional 
practice liability risk (Bucknall & Thomas, 1995, Gerdtz & Bucknall, 1999) Algorithms 
reduce the risk-adjusted outcomes for an organization by reducing the risk of medication 
error (Vanhae,cht, de Witte, & Sermeus, 2007) Within an organization, algorithm use 
provides a basis for establishing autonomy of practice within a safety net of mutually agreed 
upon actions 
Limitations of clinical algorithms are well-documented "The systematic use of 
algorithm approaches has the potential to hinder development of more flexible approaches to 
problem solving" (Gerdtz & Bucknall, 1999, p 55) It can be important to look outside the 
decision-making tree to find solutions that may apply to a specific patient or clinical 
situation Perhaps the most imminent concerns with using algorithms are having clinical 
practice dictated, losing control of practice and being monitored by others (Hartigan et al , 
2003) Another drawback is the time required to delineate all of the information in the 
algorithm, much of which does not apply to the patient at hand (Hadorn, 1994) Other 
criticisms of algorithms are the questionable clinical validity of some recommendations, 
which are not always linked to best guideline practices or systematic reviews (Hadorn) 
Renal Anemia Management Protocol (RAMP) 
A RAMP is a type of algorithm that provides standardization of care in a 
hemodialysis unit The primary components of an anemia management protocol include 
target Hgb levels, defined parameters for use of ESAs and intravenous iron, defined and 
corrective actions related to causes of a hyporesponse, and clear documentation of 
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assessments, interventions and outcomes (Michael, 2005) The measure of success of any 
anemia management protocol is its ability to guide clinical interventions to ensure every 
patient has the same standard of care If these components are directed by evidence-based 
guidelines, the achievement will be improved patient outcomes and organizational efficiency 
When examining the use of protocols in the management of anemia in hemodialysis 
patients, the evidence points to its benefits "Increased utilization of anemia management 
algorithms to guide treatment decisions for ESAs and iron therapy can allow a range of renal 
care professionals, in acute and primary care settings, to deliver consistent and effective 
treatment of patients to recommended hemoglobin target" (Macdonald, 2007, p 185) Renal 
anemia management using a treatment algorithm can reduce variability of Hgb levels by 
implementing best practices and routine Hgb assessments in the care of the patient 
(Breiterman-White, 2003, Lacson, Ofsthun & Lazarus 2003) Standardized care and 
reduction of variability in Hgb levels are essential to producing positive patient outcomes in 
the hemodialysis population 
The use of a standardized anemia protocol in the nephrology setting has the potential 
to impact patient outcomes In a recent study of target Hgb levels and risk of hospitalization, 
those patients with more months below target range were less likely to have received 
intravenous iron and were more likely to be hospitalized or die (Ishani et al, 2008) A lack 
of appropriate and timely anemia treatment could be avoided with the use of a renal anemia 
management protocol "Institutional variability in anemia care is a potentially modifiable 
factor associated with the inability to achieve target hemoglobin concentrations" (Ishani et 
a l , p 1686) 
Anemia management protocols are used extensively in North America with varying 
results related to target Hgb and ESA use A study of facility factors which affect the 
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achievement of target Hgb found that although the protocol was effective in the initial 
management of anemia management, maintenance and refinement of the protocol were a 
necessary step to improving target ranges (Chan, Lafayette, Whittemore, Hlatky, & Moran, 
2008) In a randomized controlled trial of an anemia management protocol in hemodialysis 
patients, the use of erythropoeitin was substantially reduced with no improvement in the 
achievement of target Hgb levels (Bnmble, Rabbat, McKenna, Lambert, & Carlisle, 2003) 
A study of hemodialysis patients in the Northern Alberta Renal program found no significant 
change in anemia pre-implementation to an algorithm versus post-implementation with a 
noted concern regarding the adherence of the algorithm throughout the study (Nhan, Jensen, 
& McMahon, 2007) Collins et al (2007), analyzed the likelihood of Hgb above target levels 
related to practice patterns Patients with Hgb > 130 g/L were assessed to determine if 
appropriate dose reduction in ESAs was prescribed in the month following change in Hgb 
level It was reported that approximately 70% of dialysis providers followed KDOQI 
guidelines, but this was often dependent on whether a dialysis facility was owned by a 
corporation, or it was hospital-based Hospital based dialysis facilities complied with 
guidelines more often Although anemia protocols may reduce ESA use and thus reduce costs 
to a health care institution, patient outcomes have not consistently improved, at times 
dependent on individual clinical practice and expertise in the application of these tools 
Protocol-based care by renal nurses has potential benefits of providing direction and 
structure for practice to the novice nurse, while enabling autonomy in decision-making to 
manage anemia in the hemodialysis patient It also creates an environment of critical 
thinking for the nurse to use the KDOQI guidelines for anemia, iron and ESA and assess how 
the interaction of these indices determines and guides decisions (Breiterman-White, 2003) 
Many dialysis facilities develop anemia management protocols to guide ESA dosing where 
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there are limitations to available physician and nursing time to provide anemia management 
(Werner & Levey, 2007) In addition to efficiently using ESAs, protocol use can assist the 
nurse to identify patients who are hyporesponders (Demirjian & Nurko, 2008) Protocols can 
contribute to the efficacy of resources such a lab testing 
Evaluating Patient Outcomes 
Outcomes assessment is a necessary component of nursing care because it provides 
evidence for accountability of practice (Irvine, Sidani, & McGilhs Hall, 1998) Donabedian 
introduced the model of health care quality using structure, process and outcomes as three 
quality determinants of health care (Donabedian, 1966) The Donabedian model has 
influenced the development of theories and models to delineate nursing outcomes research 
Donabedian's model focuses on the quality of health care by examining the structure of the 
environment and the processes that result in measurable outcomes Originally, this 
framework influenced studies on cost, length of stay, patient mortality, and patient 
satisfaction (Doran, 2003) It has now been used to address patient outcomes which can be 
sensitive to nursing care within a variety of health care settings (Doran) 
Those outcomes that are nursing sensitive are "relevant based on nurses' scope and 
domain of practice and for which there is empiric evidence linking nursing inputs and 
interventions to the outcome" (Doran, 2003, p vu) The National Quality Forum (NQF) 
(2004) defines nursing sensitive outcomes as outcomes that are affected, provided and /or 
influenced by nursing personnel, but for which nursing is not entirely responsible The 
relationship between nursing actions and nurse sensitive outcomes is "quantifiable but not 
necessarily causal" (National Quality Forum, 2004, p 2) 
The development of nurse sensitive outcomes began in the 1990's as a result of media 
and scientific studies identifying decreased quality of patient care and outcomes (Needleman, 
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Kurtzman, & Kizer, 2007), as well as the shortage of nurses withm the health care system 
(National Quality Forum, 2004) As a result of concerns regarding quality of care and 
nursing human resource shortages, many nursing outcomes studies have focused on nurse 
staffing, prevention of adverse events and patient safety (Aiken, Sochalski, & Anderson, 
1996, Aiken, Clarke, Sloane, Sochalski, & Silber, 2002, Cho, Ketefian, Barkauskas, & 
Smith, 2003) Many studies have demonstrated the correlation between nurse staffing, 
processes of care and patient outcomes In a meta-analysis of 28 studies, there was an 
association between RN-to-patient ratio and patient mortality and adverse effects (Kane, 
Shamhyan, Mueller, Duval, & Wilt, 2007) The link to negative outcomes such as adverse 
effects, complications or mortality is the most published area of nursing outcomes research 
(Doran, 2003) There is a gap in nursing research in the area of studying nursing actions that 
demonstrate positive patient outcomes instead of avoiding negative outcomes 
Additional challenges in nursing outcomes research are related to the limited evidence 
directly linking patient outcomes to nursing activities in acute care settings A review of 
4000 systematic reviews and 500 meta-analyses on nursing interventions and patient 
outcomes in acute care settings found that there is limited evidence to establish a direct 
association between nursing actions and patient care outcomes (Bolton, Donaldson, Rutledge, 
Bennett, & Brown, 2007) For example, patient satisfaction is identified as a nurse sensitive 
patient outcome (Doran, 2003) despite its vague definition Patient satisfaction appears to be 
patient specific, influenced by factors such as affective response and lack of standardized 
measurement Bolton et al (2004) strongly encouraged the development of standardized 
nursing interventions and patient outcomes to test the efficacy of nursing interventions across 
a patient population 
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Nursing sensitive care can be categorized into three areas (National Quality Forum, 
2004) First, patient-centered outcome measures are those outcomes of care delivered to 
patients by nurses They can include failure to rescue, falls, restraints, pressure ulcers, 
central line infections and urinary tract infections from catheters Second, nurse-centered 
intervention measures focuses on aspects of nursing intervention and processes of care, such 
as nicotine counseling Third, system-centered measures focus on organizational 
effectiveness that influences and is influenced by nursing care System centered measures 
are represented by skill mix, nursing care hours and nurse turnover There are limited 
standardized nurse sensitive measures which are applicable in the nephrology nursing setting 
Within the nephrology specialty, nurses are in a key position to influence patient-
centered outcomes Nephrology nurses are instrumental in improving anemia treatment and 
resultant outcomes because of their coordinating role in the care of the hemodialysis patient, 
working to reduce the clinical symptoms of anemia and thus influencing renal and 
cardiovascular health (Macdonald, 2007, Singh & Hertello, 2005) Nephrology nurses are 
actively involved in data collection and patient assessments, enabling identification and 
management of anemia (Bennett & Alonso, 2005) The use of a RAMP to produce target 
Hgb levels can be utilized to test of the efficacy of nurse-driven anemia management across 
the hemodialysis population 
There remains a need for nursing research to contribute to a greater understanding of 
the unique interventions of nursing and the impact these actions have on quality patient 
outcomes It is often difficult to separate the contributions of nurses from those of physicians 
and other health care providers (Naylor, 2007, Needleman, Kurtzman, & Kizer, 2007) 
Nursing actions are often intertwined with others' actions within the health care team 
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Determining actions unique to the nursing role can validate nurses' contribution to patient 
care 
Nursing Role Effectiveness Model 
The Nursing Role Effectiveness Model (NREM) was developed based on the 
Donabedian model (1966) to address the need to measure quality nursing care (Doran, 2003) 
The NREM (Figure 5) provides a framework to delineate the relationship between structure, 
process and outcomes within the context of nursing (Doran et a l , 2006) This model groups 
nursing roles into three categories and links these roles to nurse-sensitive patient outcomes 
Structure Process Outcomes 
Patient 
Age, gender, education, type 
of severity of illness, 
comorbidities 
Nurse 
Education, experience 
Organizational 
Staffing, staff mix, workload 
work environment 
Independent role 
Nursing Interventions 
Dependent role 
Execution of medical orders 
Physician initiated treatments 
Interdependent role 
Team communication, 
coordination of care, case 
management 
f Nursing-Sensitive 
patient outcomes 
Functional status, self-
care, symptom control, 
safety/adverse 
occurrences, patient 
satisfaction 
Figure 5 The Nursing Role Effectiveness Model highlighting the relationship between structure, 
process and outcomes Adapted from The Nursing Role Effectiveness Model (Irvine, Sidani & 
McGilhs Hall, 1998) 
The structure component consists of patients, nurses, and organizational variables that 
impact processes and outcomes of care (Doran, Sidani, Keating, & Doidge, 2002) Patient 
variables such as diagnosis, severity of illness, and co-morbidity can influence patient 
outcomes Nurse variables can include number of years experience, educational background 
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and clinical skills Organizational variables are those measures that emphasize nursing staff 
ratio, workload measurement and assignment patterns 
The process component identifies three roles of the nurse and categorizes these roles 
based on the functions or activities of the nurse, independent, dependent, interdependent 
roles The independent role includes those role functions such as patient assessment, 
decision-making, and intervention for which only nurses are responsible The nurse's 
dependent role includes clinical actions and judgments involved in the implementation of 
physician's orders and/or medical treatments The interdependent role encompasses all 
functions and responsibilities which nurses share with other health care professionals such as 
inter-professional communication and coordination of team-based patient care 
The outcome component of the model consists of nurse-sensitive patient outcomes 
Nurse-sensitive patient outcomes are those changes that occur m the patient as a result of 
nursing interventions (Doran, 2003) such as patient's health status, patient's perception of 
nursing care, and direct/indirect costs related to nursing care 
The NREM provides a framework for the study This study examined the 
relationship between structure, process and outcomes in renal anemia management Patient 
structural variables including age, gender, race, diagnosis, location of dialysis, number of 
days of dialysis, number of days of hospitalization, and co-morbidities influenced process 
and outcomes variables There are no nursing or organizational structural variables examined 
in this study 
The process variables differ between the control and protocol groups The control 
group nurses enact a dependent role to provide medically directed renal anemia management 
to hemodialysis patients The protocol group nurses worked within the independent role by 
using a nurse-driven protocol to provide renal anemia management to hemodialysis patients 
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The protocol group nurses also worked within the interdependent role when communication 
with the nephrologist or renal pharmacist was required according to protocol guidelines The 
differing process variables in either the control or protocol groups may have influenced the 
outcomes of the study 
Outcome variables in this study were represented by clinical lab values, dosage use of 
ESAs and intravenous iron, and cost of ESA and iron use The primary patient outcome 
examined in this study was Hgb levels This study also examined whether or not Hgb levels 
could be considered a nurse-sensitive patient outcome Other patient outcomes that were 
assessed in this study are transferrin saturation levels, ferritin levels, ESA use, and 
intravenous iron use 
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CHAPTER 3 
Methods 
This study design was framed by the Nursing Role Effectiveness Model, illustrated in 
Figure 5 and discussed in the previous chapter In this study, renal anemia was managed by 
the nurse in two different ways The control group hemodialysis nurses utilized physician's 
orders to manage renal anemia (physician-driven approach) In contrast, the protocol group 
nurses functioned independently in decision making, assessment, intervention and follow up 
to provide care to renal anemia patients using a RAMP (nurse-driven protocol) An 
examination of the control and protocol groups was completed by using a case/control study 
design This study design was chosen to provide a comparison of two groups to evaluate 
clinical patient outcomes and costs of a nurse-driven protocol approach to renal anemia 
management in contrast to an established physician-driven approach to anemia management 
Study Design 
A retrospective, non-equivalent case control group design was used to determine 
whether the process of using a nurse-driven RAMP was associated with equally effective 
patient outcomes when compared to a physician-driven anemia management approach The 
study time interval for the control group was October 2005-October 2006 The study time 
period for the NRP was from October 2007-October 2008 Using two groups from different 
settings was intended to increase the representativeness of the results 
Sources of Data 
This study used data collected and maintained by the British Columbia Provincial 
Renal Agency (BCPRA) from the Patient Record/Registration and Outcome Management 
Information System (PROMIS) database The BCPRA is under the Provincial Health 
Services Authority It is an agency that improves the health of individuals in British 
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Columbia with kidney disease by implementing province-wide solutions to the specialized 
needs of renal patients in collaboration with BC health authorities and community partners 
BCPRA manages personal health information under the BC Freedom of Information and 
Protection of Privacy Act (FOIPPA) 
PROMIS is the health information system for the BCPRA and the only province-wide 
integrated registry for renal patients in Canada This database incorporates extensive 
demographic and clinical data on all hemodialysis patients in BC Data collected from renal 
units provides information for patient management, renal unit management, research, 
continuous quality improvement, and outcomes-based planning (British Columbia Provincial 
Renal Agency, 2009a) It incorporates clinical tools to support direct patient care in addition 
to supporting resource allocation The BCPRA uses PROMIS to provide an information link 
between renal health care professionals and the renal care community in British Columbia 
The PROMIS database provides patient-specific information such as patient 
demographic information, treatment characteristics, underlying chronic conditions causing 
CKD, date of registration, lab data, and medication profiles Unit clerks in the regional 
hemodialysis units enter this information into the PROMIS database for all BC hemodialysis 
patients 
Sample 
A non-probability sample of eligible participants was drawn from all hemodialysis 
patients in the NRP on the RAMP and all hemodialysis patients in the KRP not on a protocol 
The control group consisted of a sample of hemodialysis patients («=64) with renal anemia in 
the KRP for a 1 -year period in which a standardized nurse administered anemia management 
protocol was not in use The protocol group included all hemodialysis patients («=43) in the 
NRP that were evaluated and treated using the RAMP Using the information available from 
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the NRP hemodialysis unit records, a list of those patients who were treated using the RAMP 
in October 2007 was compiled by the renal pharmacist This list, in addition to personal 
health numbers, was sent electronically to the BCPRA There was no disclosure of this list 
or information to the researcher or any party other than the BCPRA After the list had been 
sent, the BCPRA also received an electronic list of exclusion and inclusion critena, as well as 
variables to study, from the researcher Matching by gender, age and diagnosis was not 
possible due to a limited number of patients eligible for the study Figure 6 illustrates the 
selection process to determine eligibility of the control and protocol groups for the study 
Control Group Protocol Group 
82 hemodialysis patients 104 hemodialysis patients 
18 patients excluded due to 
mortality or not on 
hemodialysis for the full 
one-year study period 
61 patients excluded from study due 
to mortality, not on protocol, or not on 
hemodialysis for the full one-year 
study period 
64 control hemodialysis 
patients in study 
43 protocol hemodialysis patients in 
study 
Figure 6 Selection process for control and protocol groups 
All patients that died at any period during the study were excluded All chronic 
hemodialysis patients registered with the BCPRA and who had Hgb levels and at least one 
transferrin saturation reading in the database were included in the study 
Study Variables 
To provide descriptive comparisons of the control and protocol groups, data regarding 
the following variables were examined age, gender, race, diagnosis, co-morbidities, location 
of dialysis treatments, and length of time on dialysis Patient outcomes were measured 
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clinically by lab values and dosages of renal anemia medications such as ESA and 
intravenous iron 
The lab data specific to this study were Hgb, transferrin saturation, and ferritin levels 
Hemoglobin is the protein component of the red blood cell The Hgb was measured as g/L in 
this study Hemoglobin lab values were measured monthly for each patient Transferrin 
saturation is a lab value that indicates the amount of transferrin attached to iron and it is 
measured in percentage For this study, transferrin saturation was the primary measurable 
indicator of available iron in a patient The transferrin saturation level was measured every 
three months Ferritin levels were also used as an iron indicator Ferritin levels were 
measured intermittently based on need for assessment of iron status in the patients 
Renal anemia medications were evaluated based on patient usage A patient's ESA 
requirement was defined as the monthly dose of ESA, either Epoetin alfa or Darbepoetin alfa, 
administered during the study The intravenous iron requirement was defined as the monthly 
dose of iron, either iron dextran, iron saccharate (iron sucrose), or ferrous gluconate 
(ferrlecit) administered during the study 
Data Analysis 
Data was analyzed using SPSS 17 0 software Descriptive baseline statistics of 
gender, race, age, diagnosis, days of hospitalization, co-morbidities, and duration of 
hemodialysis were presented using n, means and/or standard deviations for the control and 
protocol groups To determine if significant differences existed between groups in Hgb 
levels, /-tests were completed Repeated measure testing was not feasible as there were 
missing data in the protocol group, limiting the number of consecutive monthly Hgb readings 
available for this test Additional data analysis was conducted using chi square test for 
categorical Hgb levels Transferrin saturation levels were compared in each group using 
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means and z-scores to determine the rate of patients reaching target levels Ferritin levels 
were compared using means and relating these values to standard guideline target ferritin 
levels A comparison of intravenous iron use per month for each group was completed by 
averaging the overall use of iron To determine the differences between the mean dose of 
ESAs between the control and protocol groups, a Mest was performed The cost of 
intravenous iron use on a monthly basis was calculated by multiplying the mean dose of iron 
each month per group and the iron cost per mg The cost of epoetin alfa was calculated by 
multiplying the average per-person monthly dose and the epoetin alfa cost per unit 
Cost Effectiveness 
A comparison of cost effectiveness of the two approaches to anemia management 
involved reviewing the control and protocol groups' usage of renal anemia medications 
Evaluation of the costs of intravenous iron and ESA's enabled the researcher to provide a 
comparison of the groups Calculating costs included determining the total average monthly 
dosage of epoetin alfa per person and multiplying by the cost per unit dose The costs of 
intravenous iron were calculated based on the average monthly dose of the group multiplied 
by the cost per mg The cost per unit of medication is based on the BCPRA summary of 
monthly costs of medications (2009) available on the BCPRA website (BCPRA, 2009) 
Ethics 
Aggregate data from the BCPRA PROMIS database was utilized for this study 
Consent for the use of any data in the PROMIS database was signed at initial point of renal 
care in British Columbia (Appendix B) and therefore every patient in this study had a signed 
consent Preliminary permission to use this database was granted to the researcher pending 
ethics approval (Appendix C) Ethics approval was granted by the University of Northern 
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British Columbia Research Ethics Board and the Northern Health Research Review 
committees (Appendices D & E) 
This study consisted of the "secondary use of information that was anonymous, 
anonymized or de-identified/coded and where the research team had no access to the 
code"(Canadian Institutes of Health Research, Natural Sciences and Engineering Council of 
Canada, Social Sciences and Humanities Research Council of Canada, 2008, p 49) There 
was no possibility of patient contact as all the data necessary were present in this database 
and sent to the researcher in codified form No personal information could be re-identified 
by the researcher after coding had occurred and therefore the privacy of the participants was 
protected 
All data was secured in a locked filing cabinet or by means of secure password-
protected electronic data files Destruction of files and database information generated for 
this study will take place no later than five years after data collection All paper-based 
information will be shredded while all computer-based information will be deleted five years 
after study completion Information for dissemination of results (presentation or publication) 
will be provided in a non-identifiable format to ensure the anonymity of subjects 
Procedures 
This study was conducted using the RAMP from NRP as an intervention in the 
protocol group The RAMP transfers anemia management of hemodialysis patients to nurses 
upon order of the nephrologist (Appendix A) This protocol was implemented as a unit-wide 
policy change in anemia management in the NRP All nurses were trained to use the protocol 
by attending two training sessions One of the sessions included a guest speaker from Fraser 
Health Authority A review of case studies with a resource nurse and a pharmacist provided 
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an opportunity to demonstrate the use of the protocol There was no dedicated protocol 
resource nurse available so nurses were working in pairs to use the RAMP 
All patients had monthly lab work drawn on a designated date to monitor Hgb levels 
The lab work also included iron studies indicated by transferrin saturation (TSAT) and 
ferritin levels at beginning of protocol, every three months thereafter and as needed 
Depending on Hgb status, the protocol provides step-wise instructions on how to titrate an 
erythropoietic stimulating agent (ESA) or provide iron therapy Steps for monitoring Hgb 
status were also provided in the protocol If the Hgb was 126 g/L or higher with a >20 g/L 
increase since last Hgb, the physician was notified The targeted Hgb for this protocol was 
between 110-125 g/1 Transferrin saturation level was targeted between 20% and 50% 
Ferritin levels were drawn every three months and as needed These targets were agreed upon 
by the protocol committee based on the KDOQI guidelines at the time of printing 
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CHAPTER 4 
Results 
Comparison of Control and Protocol Groups 
This study presented two groups in comparison The control group consisted of 
hemodialysis unit patients from three centres in the KRP, Kelowna General Hospital (KGH), 
Rutland, and Vernon, treated without a RAMP The protocol group consisted of 
hemodialysis patients from three centres in the NRP, University Hospital of Northern British 
Columbia (UHNBC), Fort St John, and Terrace Northwest, treated using a RAMP 
Throughout this chapter, the control group data will be presented first This will allow a 
clear comparison of the group without the use of a RAMP to the protocol group Table 4 
shows the distribution of patients in each group 
Table 4 
Distribution of Patients in the Control and Protocol Groups 
Group n Percent 
KGH 27 422 
Rutland 16 25 0 
Vernon 21 32 8 
Total 64 100 0 
UHNBC 29 67 4 
Fort St John 7 16 3 
Northwest 7 16 3 
Total 43 100 0 
Classification of descriptive data in the control and protocol groups is shown in 
Tables 5, 6 and 7 Table 5 includes a brief summary of patient demographic characteristics 
of gender, age and race data The term gender was defined as a patient's biological sex 
Caucasian and First Nations groups are displayed as these are the predominant races in each 
group Table 6 shows the age distribution of patients in each group 
Control 
Protocol 
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Gender n (%) 
Male 
Female 
Age (yrs) 
Mean ± SD 
Range 
Race n(%) 
Caucasian 
First Nations 
34(53 1) 
30 (46 9) 
62 0 ±15 4 
64 
51 (79 7) 
2 (3 1) 
Table 5 
Gender, Race, and Age of Patients in Control and Protocol Groups 
Variable Control Protocol 
30 (69 8) 
13(30 2) 
61 6± 13 8 
65 
29 (67 4) 
12 (27 9) 
Note Values enclosed in parentheses indicate percentage 
Patients in the control group (n=64) had a mean age of 62 0 with a standard deviation 
of 15 4 years Approximately 84% of all the patients in the control group were in the age 
bracket of 41-80 years old The protocol group (n=43) had age data very similar to the 
control group with a mean age of 61 6 years and a standard deviation of 13 8 years The age 
distribution of the protocol group was very similar to the control group with approximately 
84% of all patients in the age bracket of 41-80 years old 
Table 6 
Age Distribution of Control and Protocol Groups 
Age (years) 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
91-100 
Control n(%) 
1 
2 
2 
9 
12 
13 
21 
4 
0 
(16) 
(3 1) 
(3 1) 
(14 1) 
(18 8) 
(20 3) 
(32 8) 
(6 3) 
(0) 
Protocol /?(%) 
0 
1 
3 
5 
11 
12 
9 
1 
1 
(0) 
(2 3) 
(7 0) 
(116) 
(25 6) 
(27 9) 
(20 9) 
(2 3) 
(2 3) 
There were significant differences between the groups for gender split or diagnosis 
There was a considerably greater percentage (70%) of males in the protocol group (Figure 7), 
while there was an approximate gender split of 50% in the control group Race data 
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indicated large differences between the groups The protocol group had almost a third of its 
patients identified as First Nations while the control group had less than 4% (Figure 8) The 
control group had approximately 10% of patients in an unidentified other race category 
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Figure 7 Comparison of gender split in control and protocol groups 
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Figure 8 Comparison of race in control and protocol groups 
Hospitalization days, hemodialysis days, diagnosis and co-morbidity data are 
presented in Table 7 The hospitalization data are measured by days hospitalized during the 
study Hemodialysis days pre-study are displayed as mean days Diagnosis was categorized 
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based on the most prevalent causes of kidney disease with an "other" category which did not 
identify a specific diagnosis in the database Co-morbidities were also reported as frequency 
and percent incidence 
Table 7 
Hospitalization, Hemodialysis Days, Diagnosis and Co-morbidities for the Control and 
Protocol Groups 
Variable value 
0 days n (%) 
1-20 days n (%) 
>21 daysn(%) 
Median 
Mean 
1-500 days 
501-1000 days 
1001-1500 days 
1501-2000 days 
2001-2500 days 
>2500 days 
Diabetic Nephropathy 
Renal Vascular disease 
Chronic Renal Failure 
Polycystic Kidney Disease 
Glomerulonephritis 
Obstructive Uropathy 
IgA Nephropathy 
Other 
Diabetes 
LVH 
CHF 
CVA 
MI 
DYSL 
HTN 
Control 
Days of Hospitalization 
33(516) 
19 (29 7) 
12(18 7) 
Hemodialysis days 
pre study 
882 
1235 
23 (35 9) 
14(21 9) 
9(14 1) 
8(12 5) 
4(6 3) 
6(9 4) 
Diagnosis 
15 (23 4) 
15 (23 4) 
13(20 3) 
3(4 7) 
3(4 7) 
1(16) 
1(16) 
13(20 3) 
Comorbidity 
19 (29 7) 
37 (57 8) 
40 (62 5) 
43 (67 2) 
44 (68 8) 
13(20 3) 
52(813) 
Protocol 
19(44 2) 
14 (32 6) 
10(23 2) 
790 
1222 
14 (32 6) 
14 (32 6) 
7(16 3) 
3 (7 0) 
2(4 7) 
3(7 0) 
21 (48 8) 
6(14 0) 
5(116) 
2(4 7) 
3(7 0) 
2(4 7) 
2(4 7) 
2(4 7) 
28(65 1) 
34 (79 1) 
40 (93 0) 
41 (95 3) 
41 (95 3) 
15(34 9) 
41 (95 3) 
Note LVH-=left ventricular hypertrophy, CHF=Congestive Heart Failure, CVA= Cerebrovascular Accident, 
MI=Myocardial Infarction, DYSL= Dyshpidemia, HTN= Hypertension 
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Nearly 50% of patients in the control group were not hospitalized during the study 
period Over 70% of the patients had 1500 hemodialysis days or less pre-study Diabetic 
nephropathy, renal vascular disease and chronic renal failure were the leading primary 
diagnoses for the group, with just over 20% incidence respectively The control group had 
approximately 20% of patients within the "other" diagnosis category The primary co-
morbidity of the control group was hypertension (81 3%) Myocardial infarction and 
cerebral vascular accident were present in just over two-thirds of the patients in the control 
group 
Approximately 45% of patients in the protocol group had no hospitalization days 
Over 80% of patients had 1500 hemodialysis days or less Nearly 50% of the protocol group 
had a primary diagnosis of diabetic nephropathy The protocol group had about 10% less 
incidence of renal vascular disease and chronic renal failure compared to the control group 
The protocol group had a high incidence of cardiac co-morbidities Over 90% of patients in 
the protocol group had hypertension, myocardial infarction, cerebral vascular accident and 
congestive heart failure identified as co-morbidities 
The control and protocol groups were similar in total hospitalization days, number of 
hemodialysis days pre-study, and incidence of some primary diagnosis The percentage of 
patients with no hospitalizations days at 51 6 and 44 2 percent for control and protocol 
groups respectively were not importantly different (Table 7) Most of the patients in both 
groups had less than 1000 days of hemodialysis with similar mean days of over 1200 days 
The median hemodialysis days pre-study differed for the control and protocol groups at 882 
and 790 days respectively Both groups had similar incidence of polycystic kidney disease, 
glomerulonephritis, obstructive uropathy, and IgA nephropathy 
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Based on diagnosis and co-morbidity incidence, there are considerable differences 
The control group had approximately 25% less incidence of diabetic nephropathy compared 
to the protocol group (Table 7) The control group had a 9% greater incidence of renal 
vascular disease than the protocol group The protocol group had over 90% of patients with 
cardiac co-morbidities such as myocardial infarction, congestive heart failure and left 
ventricular hypertrophy compared to the control group with approximately 30 % less 
incidence (Figure 9) The protocol group had over 30% more incidence of diabetes as a co-
morbidity compared to the control group (Figure 9) 
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Figure 9 A comparison of incidence of co-morbidities in the control and protocol groups 
Note LVH- Left Ventricular Hypertrophy, CHF- Congestive Heart Failure, CVA- Cerebrovascular Accident, 
MI- Myocardial Infarction 
Data Analysis 
Outcome Data 
Hemoglobin Levels 
Initial data analysis focused on comparison of Hgb means between the control and 
protocol group Group statistics demonstrated that the means between the groups were 
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similar (Figure 10) The largest difference of means was 4 g/L Data from more than 14 
protocol group patients was missing for the months of December, March and July The 
control group had much less missing data with an average of 3 cases per month and a 
maximum of 6 cases missing in August The protocol group number of patients ranges from 
21-43 and the control group number ranges from 58-61 
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Figure 10 A comparison of hemoglobin level means between the control and protocol groups 
An independent, non directional, Miest was performed to compare differences of 
mean Hgb levels between the protocol group and control group A Levene's test for equality 
of variances indicated ap > 05 value for each month, suggesting that the variability in the 
groups was consistent and therefore equal variances was assumed in all cases (Appendix F) 
Calculation of Cohen's d effect size indicated that every month had trivial or small, effect 
size results (Appendix F) For purposes of this study, trivial effect size in a two-group test of 
mean differences was defined as <0 20, a small effect size was between 0 20 and 0 49, a 
medium effect size was between 0 50 and 0 79, and a large effect size was 0 80 or greater 
(Cohen, 1988) The Mest for equality of means indicated ap > 05 for every month, and in 
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addition to effect sizes, no significant statistical differences in Hgb means were identified 
between the groups (Appendix D) 
Following the /-test, Hgb data were regrouped into three categories below target, 75-
109g/L, target, 110-125 g/L, above target, 126-145 g/L These categories were based on Hgb 
values that indicate below target, target and above target according to KDOQI guidelines 
used to develop the renal anemia management protocol (Appendix G) To determine whether 
the Hgb categorical outcomes of the groups were statistically different, a chi square test of 
independence was conducted In every category, the observed and expected values were 
similar The p values were > 05 every month indicating both groups were not statistically 
different from each other For every month there was no indication that the ratios of below 
target, target or above target differed between the protocol and control groups 
Although categorizing the data into above or below targets (110-125 g/L) was used in 
the previous testing, neither category could be considered more unsafe for the patient than the 
other Categorizing the data into two categories to indicate on or off target was useful for 
further testing to determine if there were differences in the control and protocol group Hgb 
means The on target category was defined as Hgb values of 110-125 g/L, while off target 
category was defined as all Hgb values outside the target category range To determine if the 
Hgb observed values of the groups were statistically different, chi square testing was 
performed For all months there was no evidence of statistically significant differences 
between the groups, with on target or off target values/? > 05 in all cases (Appendix H) 
Because of the consistent chi-square statistics indicating the control and protocol groups were 
not statistically different from each other, no significant differences were found between the 
groups based on categorical comparison of on and off target Hgb 
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To improve sensitivity of the testing, a repeated measures test under the General 
Linear Model was attempted There were limited number of protocol patients with 
consecutive monthly Hgb levels present in the database (n=S) therefore conducting a 
repeated measures statistical test was not practical 
Transferrin Saturation Levels 
Transferrin saturation results were reviewed to determine if there were differences 
between the groups Transferrin saturation (TSAT) levels have a direct impact on the 
efficacy of erythropoietin stimulating agents as well as being a key indicator to assess iron 
needs (Kalantar-Zadeh et al , 1998, Pisoni et al, 2004) The protocol group using RAMP 
had TSAT levels drawn every three months routinely, periodic levels drawn dependent on the 
TSAT level, and follow up levels drawn after the use of intravenous iron The control group 
had monthly TSAT levels drawn The number of patients with TSAT levels differs 
considerably each month, particularly in the protocol group (Tables 8 and 9) 
Table 8 
Control Group Mean Transferrin Saturation Levels and z Scores 
Month 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
N 
61 
59 
61 
60 
60 
60 
61 
59 
60 
61 
55 
60 
Target Mean 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
Control Mean 
0 13 
0 13 
0 16 
0 16 
0 16 
0 15 
0 17 
0 16 
0 17 
0 15 
0 15 
0 17 
SD 
0 07 
0 06 
0 07 
0 06 
0 06 
0 07 
0 10 
0 07 
0 07 
0 06 
0 06 
0 07 
z-Score % Patient 
102 
1 10 
0 59 
0 72 
0 72 
0 75 
0 27 
0 58 
0 47 
0 74 
0 82 
0 53 
15 
14 
28 
24 
24 
23 
39 
28 
32 
22 
21 
30 
To compare the TSAT means of the control and protocol groups, each mean was 
compared to the number of standard deviations above or below the target, using the KDOQI 
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guidelines value of TSAT >0 2 as the target mean Each z-score was calculated based on the 
number of standard deviations from the target The control group z-scores were consistently 
above zero while the protocol group z-scores were below zero The z-score was converted to 
a percentage based on assumed normality of distribution The percentage of patients 
reaching the target TSAT levels are presented in Table 8 and 9 
Table 9 
Protocol Group Mean Transferrin Saturation Levels and z-Scores 
Month 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
n 
8 
39 
9 
32 
34 
14 
14 
36 
9 
13 
27 
14 
Target Mean 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
>0 2 
Protocol Mean 
0 34 
0 28 
0 35 
0 27 
031 
0 32 
0 35 
0 28 
0 30 
0 28 
031 
0 30 
SD 
0 17 
011 
021 
0 08 
0 10 
0 19 
0 15 
0 12 
0 22 
0 09 
0 12 
0 14 
z-Score 
-0 86 
-0 73 
-0 72 
-0 87 
-1 10 
-0 62 
-100 
-0 65 
-0 47 
-0 91 
-0 85 
-0 69 
% Patients 
81 
77 
76 
81 
86 
73 
84 
74 
68 
82 
80 
75 
The percentages of patients reaching targets indicate that the control group had TSAT 
means that were consistently below acceptable targets (Figure 11) The control group had an 
interquartile range of 22-28% of patients reaching target mean TSAT levels while the 
protocol group had an interquartile range of 75-81 % of patients reaching those levels With 
less serum iron saturation testing and the use of the RAMP, the protocol group had reached 
acceptable TSAT levels 
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Figure 11 The percentage of patients reaching target transferrin saturation levels in the control and 
protocol groups 
Ferritin Levels 
Ferritin is a protein that stores iron that is released and transported to necessary areas 
in the body Ferritin levels were not consistently available on a monthly basis in the control 
group The protocol group had ferritin levels drawn based on the RAMP recommendations 
The ferritin monthly mean levels are shown in Figure 12 KDOQI guidelines recommend 
maintaining ferritin levels at 200-500 pg/ml during ESA treatment to avoid iron deficiency in 
hemodialysis patients (National Kidney Foundation, 2006) The protocol group had monthly 
mean ferritin levels above 600 ug/L throughout the study No ferritin levels were available in 
the control group in May and August Control group monthly mean levels were below 500 
pg/L in each month except November Data on ferritin levels were low for patients in the 
protocol group and not consistently available for patients in the control group, and therefore 
statistical testing to compare the means was not feasible 
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Figure 12 Monthly mean ferritin levels (ug/L) in the control and protocol groups 
Analysis of Renal Anemia Medication Use 
Intravenous Iron 
A comparison of the use of intravenous iron between the control and protocol groups 
required an examination of the elemental iron in each medication The control group used 
intravenous iron saccharate while the protocol group used intravenous iron gluconate and 
iron dextran Although different iron preparations are used, each dose refers to the amount of 
elemental iron in the dose 
In both groups, the number of patients that used intravenous iron at any point in the 
study was inconsistent Patients were given intravenous iron based on need At any given 
point in the study, there were 10-17 control group patients and 13-22 protocol group patients 
using intravenous iron Mean dosages were used to determine the monthly use of 
intravenous elemental iron in each group, and comparisons of total mean group dosages of 
the control and protocol groups were performed 
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The trend in iron use for both groups differs throughout the study The protocol 
group used less intravenous iron than the control group in every month with the exception of 
October, November and August (Figure 13) The control group required approximately 
9,500 mg more of intravenous iron over the course of the study when compared to the 
protocol group 
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Figure 13 Total group monthly intravenous iron use in control and protocol groups 
Erythropoietin Stimulating Agents 
Erythropoietin stimulating agents were divided into two categories Darbepoetin and 
epoetin alfa are the two preparations of the drug used in this study Due to low numbers of 
patients using darbepoetin (n= 2-6), an analysis of effect size was conducted to determine the 
chance of Type II error Table 10 highlights the mean difference and effect size of the 
relationship between the mean dosages of both groups The standard deviation of the control 
group was used in the calculations since this is the group for which effectiveness of the 
protocol was being compared Seven out of twelve months had medium effect sizes, four had 
large effect sizes and one had small effect sizes A /-test indicated there were no significant 
differences (p> 05) in mean values between the control and protocol groups in the 
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darbepoetin dosage category This is likely a type II error because the /-test could not detect 
significant differences, despite the evidence of medium effect sizes in seven out of twelve 
months The /-test is lacking sensitivity due to small sample sizes 
Table 10 
Effect Size of the Difference Between the Means of Control and Protocol Darbepoetin Alfa 
Dosages 
Month 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
Mean difference 
-89 07 
-101 32 
-115 82 
-130 28 
-79 60 
-79 60 
-50 65 
-123 05 
-101 32 
-86 85 
-86 85 
-115 82 
SD 
13170 
139 36 
139 36 
135 70 
156 56 
156 56 
149 58 
149 58 
149 58 
145 32 
145 32 
145 32 
Cohen's d 
0 67 
0 72 
0 83 
0 96 
051 
051 
0 33 
0 82 
0 68 
0 60 
0 60 
0 80 
Effect Size 
Medium 
Medium 
Large 
Large 
Medium 
Medium 
Small 
Large 
Medium 
Medium 
Medium 
Large 
Note p> 05 for all months analyzed 
A majority of patients in both groups were using epoetin alfa as an erythropoietin 
stimulating agent Equal variances were assumed in all months with the exception of April, 
May and June (Appendix I) Effect sizes for 9 out of 12 months demonstrated small effect 
sizes (Appendix I) An independent, non directional /-test was performed to determine if 
there were differences between the means of epoetin alfa dosages in the control and protocol 
dosages For each month, there were no significant differences (p > 05) between the mean 
dosages of epoetin alfa of the control and protocol groups (Table 11) 
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Table 11 
The t-testsfor the Equality of Means in Epoetin Alfa Dosages Between the Control and 
Protocol Groups 
Month 
October mean epoetin alfa dose 
November mean epoetin alfa dose 
December mean epoetin alfa dose 
January mean epoetin alfa dose 
February mean epoetin alfa dose 
March mean epoetin alfa dose 
April mean epoetin alfa dose 
May mean epoetin alfa dose 
June mean epoetin alfa dose 
July mean epoetin alfa dose 
August mean epoetin alfa dose 
September mean epoetin alfa dose 
Equal variances 
assumed 
assumed 
assumed 
assumed 
assumed 
assumed 
not assumed 
not assumed 
not assumed 
assumed 
assumed 
assumed 
/ 
0 153 
0 082 
0 197 
-0 159 
-0 497 
-0 719 
-1209 
-1214 
-1 176 
-1243 
-1215 
-1 113 
df 
93 
90 
90 
91 
88 
88 
59 
57 
53 
90 
90 
89 
P 
88 
93 
84 
87 
62 
47 
27 
27 
25 
22 
23 
27 
To examine the average use of epoetin alfa per person in the control («=55) and 
protocol («=37) groups, the sum of the mean averages were divided by the number of 
patients using epoetin alfa in the group Figure 14 indicates that the average use at the 
beginning of the study was very similar for the control and protocol group at approximately 
48,000 and 50,000 units per person respectively The use of epoetin alfa in the control group 
decreased progressively by approximately 3,000 units in May and then trended to levels 
similar to October results by the end of the study The use of epoetin alfa in the protocol 
group trended upwards by almost 10,000 units per person, per month by the end of the study 
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Figure 14 The average dose of epoetin alfa per person in the control and protocol groups 
Confounding Variables 
To examine the effect any extraneous variables may have on the ESA dosages 
between the groups, /-tests were performed to determine if there were statistically significant 
differences between potential confounding variables There were noticeable differences in 
gender, race and co-morbidity frequency in the groups Further non directional /-tests show 
that there were significant differences (p< 05) between the incidence of diabetes, 
cerebrovascular accidents, congestive heart failure, myocardial infarction and hypertension 
between the control and protocol groups There were no significant differences of 
dyshpidemia incidence means between the control and protocol groups 
An examination of the entire group of patients was performed to determine if there 
were differences in race and co-morbidities The groups were tested together due to the low 
numbers of First Nations patients in the control group There were no significant differences 
(p> 05) in the total group of patients (both control and protocol combined) between 
Caucasian and First Nations means for all co-morbidity incidence 
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Next, a /-test to show if there were any significant gender differences in the control 
and protocol groups for use of Epoetin Alfa was completed Results indicated p > 05 for 
every month, therefore no significant differences were detected A /-test to determine if there 
were significant differences in each group between Caucasians and First Nations use of 
Epoetin Alfa was performed thereafter There were no significant differences between these 
races and Epoetin Alfa dosages in all the months in the control group and 10 out of 12 of the 
months in the protocol group (p > 05) 
An attempt to find significant differences between the iron dosages and co-morbidity 
incidence was not feasible due to low numbers of patients using each preparation of 
intravenous iron in each group The tables for each of these /-tests were not included in this 
study 
Economic Analysis 
An analysis of the cost effectiveness of the protocol was assessed, by examining the 
costs of intravenous iron and epoetin alfa treatments A comparison of the control and 
protocol group provided information regarding the cost of a non-protocol and protocol 
approach to renal anemia management All costs for medications are based on BCPRA 2009 
summary of monthly drug costs (British Columbia Provincial Renal Agency, 2009b) 
Intravenous Iron 
When comparing monthly expenses for intravenous iron, the control group had 
elevated costs related to higher use of iron and the type of iron used The cost of iron 
saccharate is $36 63/100 mg, iron dextran is $16 83/100 mg and iron gluconate is $19 96/100 
mg (British Columbia Provincial Renal Agency, 2009b) Over the time period of the study, 
the total intravenous iron cost of the control group was approximately $17,000 more than the 
protocol group (Fig 15) 
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Figure 15 Total monthly cost of intravenous iron in control and protocol groups 
Epoetin Alfa 
An analysis of the cost of epoetin alfa treatment in the control and protocol group is 
presented in Table 12 The cost of epoetin alfa is $17 11 per 200 units (British Columbia 
Provincial Renal Agency, 2009b) Although both groups began with similar costs, the 
protocol group had significant cost increases during the study By completion of the study 
the costs were almost $950 dollars more per month per person in the protocol group The 
overall cost difference per person during the study is $8,135 more in the protocol group 
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Table 12 
Average per Patient Cost for Epoetin Alfa in the Control and Protocol Groups 
Month 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
Group 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Control 
Protocol 
Avg Dosage per Patient 
48640 
50261 
48785 
50377 
49799 
50594 
49711 
53173 
48770 
55567 
46840 
55232 
46189 
57760 
45899 
59429 
46189 
58857 
46912 
59389 
47709 
60040 
48142 
59352 
Cost per Month ($) 
4159 
4297 
4171 
4307 
4258 
4326 
4250 
4546 
4169 
4751 
4005 
4722 
3949 
4938 
3924 
5081 
3949 
5032 
4011 
5078 
4079 
5133 
4116 
5074 
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CHAPTER 5 
Discussion 
In this case-control study, a group of hemodialysis patients using a RAMP was 
compared to a control group of hemodialysis patients for whom a protocol was not utilized 
The groups were comparable in age, time on hemodialysis and number of days without 
hospitalization 
Research Question One 
In the hemodialysis population, does using a nurse-driven RAMP enable patients to 
maintain target Hgb levels as effectively as a non-protocol based physician-driven approach9 
When examining the Hgb level means throughout the study, the control and protocol groups 
maintained target Hgb levels Using /-tests, there were no significant differences (p > 05) in 
the Hgb levels between the groups In addition, when the groups were separated into below 
and above target categories, there were no significant differences between the protocol and 
control groups In this study, hemodialysis patients in the protocol group maintained Hgb 
target levels as effectively as hemodialysis patients in the control group These findings 
provide some evidence to indicate that the use of nurse-driven anemia protocols can 
contribute to safe patient outcomes in the hemodialysis setting, as it pertains to maintaining 
target hemoglobin levels 
Research Question Two 
Is there a relationship between an anemia management practice approach and Hgb 
levels, iron levels, intravenous iron use, and erythropoietin use in the hemodialysis setting9 
Throughout the study, iron saturation levels tended to reach target levels for the protocol 
group The measure of iron saturation levels available for red blood cell production is not a 
direct indicator of effective anemia control but evidence shows a strong association between 
68 
transferrin saturation (TSAT) levels and anemia control (Pisoni et al, 2004) KDOQI 
guidelines recommend TSAT levels > 0 20 to prevent iron deficiency anemia (National 
Kidney Foundation, 2006) For the protocol group, approximately 78% of their patients 
reached TSAT levels of 20, while approximately 25% of the control group reached that 
level The RAMP has specific interventions targeted at treating low TSAT levels 
The low rates of acceptable TSAT levels in the control group did not appear to affect 
the achievement of target Hgb levels Nothing in literature reviewed for this study addressed 
the impact of low TSAT on target Hgb, with the exception that TSAT levels do not have a 
direct cause and effect relationship with hemoglobin level, they are only associated between 
the variables Further studies examining TSAT levels and their relationship with target Hgb 
levels in hemodialysis patients are required to determine acceptable TSAT levels for renal 
anemia management 
The control group had monthly TSAT levels drawn, which reflected intensive 
monitoring, but did not appear to contribute to better health outcomes The TSAT levels 
remained far below target levels throughout the study The protocol group was tested for 
TSAT levels every three months and randomly depending on intravenous iron use Although 
the protocol group was tested less frequently, the patient outcomes were much better, with 
the added benefit of less discomfort to the patient and greater cost savings The cost of 
serum TSAT testing is $19 86 (A Arsenault, economics assistant, BCMA, personal 
communication, April 27, 2010) Monthly TSAT testing appears to be a costly and 
unnecessary intervention for patients 
Ferritin levels differed noticeably between the control and protocol groups Ferritin 
levels should be maintained at 200-500 ug/L to prevent iron deficiency in hemodialysis 
patients treated with an ESA (National Kidney Foundation, 2006) In this study, the control 
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group had ferritin levels consistently below 250 ug/L with the exception of two months 
where data was unavailable In spite of these two absent data points, the average ferritin 
level for the duration of the study was close to 300 ug/L Unfortunately there was sporadic 
data available in the control group due to testing based on individual needs and not as a 
scheduled unit routine As a result, statistical testing was not feasible This finding speaks to 
the need to monitor ferritin levels in practice, based on a more standardized protocol such as 
the RAMP utilized in this study 
The protocol group had monthly ferritin levels greater than 600 ug/L The average 
ferritin level for the protocol group was close to 800 ug/L Evidence shows that 
hemodialysis patients often have elevated ferritin levels related to inflammation, which 
interferes with the synthesis and clearance of ferritin (Easom, 2006) Elevated ferritin levels 
pose a problem when using stringent protocol guidelines The RAMP uses ferritin levels of 
>500 ug/L as an indication of iron overload although in the protocol group, this may be 
associated with underlying inflammation related to cardiac co-morbidities in the patients 
Further research is recommended to determine if there are statistically significant differences 
in ferritin levels between the groups and the implications that these differences may have for 
anemia management As well, further investigation into validity of using ferritin as an iron 
status indicator in the hemodialysis population is suggested 
The use of intravenous iron was also an indicator of anemia management that differed 
between the groups Although different intravenous iron preparations were used in each 
group, a comparison of elemental iron in each preparation allowed a comparison of iron use 
Iron doses were greater in the control group resulting in an overall use that was nearly 10 g 
more than the protocol group The higher iron doses in the control group were inconsistent 
with the low TSAT levels Results from this study suggest that iron deficiency was present 
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in the control group despite treatment with intravenous iron Low transferrin saturation 
despite treatment indicates a need to further investigate the relationship between transferrin 
saturation and iron deficiency and its impact on anemia management in hemodialysis 
patients 
When examining the repercussions of using intravenous iron at higher rates, most 
health care institutions focus on costs The costs of intravenous iron are substantial, 
depending on the type of iron in use The cost of iron saccharate ($36 63/1 OOmg) is much 
higher than iron gluconate ($19 96/1 OOmg) and iron dextran ($16 83/1 OOmg) (British 
Columbia Provincial Renal Agency, 2009b) The control group used iron saccharate 
exclusively, contributing to the inflated costs of iron treatment in comparison to the protocol 
group, which used iron gluconate and iron dextran The overall protocol group intravenous 
iron cost over the 12 month study period was $17000 less than the overall control group cost 
These are significant cost savings that could be related the type of iron used, in addition to 
the use of a protocol that facilitated the appropriate treatment of iron deficiency 
Another variable which showed differences between groups was the overall use of 
erythropoietin stimulating agents Although there was no statistically significant differences 
(p > 05) between the means of epoetin alfa dosages of each group, the average dose per 
person showed trends that indicate slightly greater use in the protocol group In the last 8 
months of the study, the protocol group displayed an increased use of nearly 10000 units per 
person compared to the control group The protocol group had over $8000 higher costs per 
person for the use of epoetin alfa compared to the control group during the study The high 
cost of this medication and the trend of increased use of epoetin alfa present a concern about 
the financial implications of standardized dosing in a RAMP such as the one used for this 
study 
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The increased use of epoetin alfa in the protocol group is an indication of 
hyporesponse to the drug and hyporesponse was considered a confounding variable in this 
study Evidence demonstrates that hyporesponse to ESAs are associated with inflammation 
The higher incidence of cardiovascular co-morbidities in the protocol group could also 
provide an explanation for hyporesponse to epoetin alfa The influence of prevalence of 
cardiac co-morbidities was not considered a confounding variable at the study design stage 
Furthermore, the higher incidence of diabetes in the protocol group and the ensuing 
inflammatory process related to infection, microvascular disease, and atherosclerosis could 
play a role in hyporesponse to epoetin alfa 
Hyporesponse to epoetin alfa in conjunction with higher ferritin levels in the protocol 
group suggests the need for further investigation to determine if the protocol group had a 
higher incidence of inflammatory disorders or processes as compared to the control group 
Further need for prospective trials to examine the relationship between the presence of 
cardiac comorbidities in hemodialysis patients and response to ESA's are also indicated 
Another potential confounding variable is the higher First Nations population in the 
protocol group Although this study attempted to explore a relationship between ethnicity 
and ESA response through correlational analysis, limited numbers of patients from First 
Nations background in the control group prevented this Future research is warranted to 
examine if there is a relationship between First Nations ethnicity and ESA response 
The higher population of First Nations people in Northern British Columbia is a 
predictable finding from this study The challenges that the Northern Renal program faces is 
unique in the province Northern British Columbia has nearly 16% of its population 
identified as aboriginal located at 80 reserve First Nations communities (BC Stats, 2007a, 
Tabobondung, 2007) The First Nations populations in Northern British Columbia are both 
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numerous and diverse compared to the rest of the province The overall prevalence of 
diabetes among First Nations populations in BC is at least 40% higher than that of the 
general BC population The prevalence of diabetic nephropathy is much higher in First 
Nations than in the general population, and the rates range from 25-60% following 15 to 20 
years with diabetes (Whiteside, 1994) The risk of developing ESRD from diabetes in First 
Nations populations is three times higher than the general population and of those with 
ESRD, the relative risk of starting dialysis is 6 5 times higher than the general population 
(Young, Kaufert, McKenzie, Hawkins, & O'Neil, 1989) This finding indicates a need to 
account for the type of population that the NRP serves to assist in appropriate health service 
planning, funding and policy development in this region 
This study explored patient structural variables and the independent or dependent role 
of the nurse resulting in nurse sensitive outcomes As indicated previously, the patient 
variables, such as co-morbidities, may have a significant influence on the patient outcomes of 
ESA use There is no conclusive evidence to indicate that higher ESA use in the protocol 
group is directly related to the independent role of the nurse in renal anemia management 
The higher ESA use may be related to deficiencies in the protocol in regards to dosing for 
patients with cardiac co-morbidities In contrast, the patient outcome of increased use of 
intravenous iron could be related to the dependent role of the nurse and lack of decision-
making tools to properly treat iron deficiency The complexity of the interrelationship 
between patient outcomes such as Hgb, ferritin, TSAT, iron and ESA use, as well as patient 
variables such as diagnosis, race and the presence of co-morbidities complicates evaluating 
the process variables of the independent and dependent roles of the nurses In spite of 
challenges of examining the roles of nurses in this study, the protocol nurses are primarily 
responsible for ensuring that patients reach target Hgb levels Due to iron levels outside of 
73 
the parameter of the RAMP, in this case higher ferritin levels in the protocol group, physician 
or pharmacist consultation was required 
The NREM provided a framework to determine how nurse-driven anemia 
management contributes to nurse sensitive patient outcomes It was useful to conceptualize 
renal anemia management through a structure, process and outcome model that specifically 
examines the impact that nursing actions have on patient outcomes The structural 
component was applicable to this study by focusing on the patient variables which can 
impact patient outcomes In this study, patient co-morbidities and ethnicity had the potential 
of influencing patient outcomes This study did not examine nursing or organizational 
structural components as outlined by the NREM The influence of individual nursing 
variables such as education and experience, as well as organizational variables of staffing or 
hospital policy on patient outcomes in this study are unknown at this time Nursing research 
to test the NREM in the hemodialysis setting, to further explore nursing and organizational 
variables and their impact on patient outcomes is suggested 
Examining the process component by delineating the roles that nurses acquire to 
provide renal anemia management to the hemodialysis patient indicated that the control 
group maintained a dependent role while the protocol group used a combination of 
independent and interdependent roles The NREM also showed the relationship between the 
structure and process and its impact on outcomes In this study, physiological patient 
biomarkers such as Hgb were identified as potential nurse sensitive outcomes, directly 
influenced by nursing roles and patient variables Examining nurse sensitive outcomes in the 
hemodialysis setting informs the health care system of the contributions of nephrology 
nursing practice 
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In this study, the protocol nurses were the renal care professionals that provided most 
of the treatment care for the RAMP resulting in physiological patient outcomes The 
activities associated with the independent role of the nurse included assessment of lab work, 
assessment of patient's condition, decision-making regarding a plan of care and intervention 
according to protocol guidelines Therefore, using a nurse-driven RAMP in hemodialysis 
patients may have resulted in Hgb levels identified as a clinical nurse sensitive patient 
outcome 
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CHAPTER 6 
Conclusion 
This study examined patient outcomes pertaining to the use of a RAMP to care for 
hemodialysis patients The study provided some evidence that the use of a nurse-driven 
protocol is as effective as a non-protocol, physician-based practice approach to renal anemia 
management Each group reached and maintained acceptable target Hgb ranges during the 
course of the study The study also demonstrated that the relationship between the practice 
approach to anemia management and Hgb levels, iron levels, intravenous iron use and ESA 
use cannot be evaluated effectively based on the complexity of the interrelationship between 
the variables 
Nurses at the NRP were meeting nephrology nursing standards by utilizing a RAMP 
The change in decision-making structure had enabled nurses to work to a full scope of 
practice in managing renal anemia by increasing their responsibilities in the process of 
assessment, planning and evaluation of hemodialysis patients Through the use of a decision 
support tool, namely the RAMP, nurses at the NRP were maintaining acceptable target Hgb 
levels in their hemodialysis patients 
Although this tool enabled nurses to provide the necessary actions to maintain Hgb 
levels, evidence from this study also indicated a need to examine the use and dosing of 
intravenous iron preparations and their relationship to iron level indicators in addition to ESA 
dosing and its impact on Hgb levels The relationship between these indicators was found to 
be more complex than anticipated at the study outset A link between these indicators was 
assumed but results from this study demonstrated otherwise For example, the literature 
provided a strong association between adequate TSAT levels and target Hgb levels although 
results from the control group in this study demonstrated otherwise Also, the influence of 
76 
confounding variables such as race, diagnosis and co-morbidity incidence may have added to 
the complexity of examining target Hgb levels in the hemodialysis population 
The higher incidence of cardiac co-morbidities and diabetes in the hemodialysis 
patients treated by the NRP challenges the idea that a standardized protocol fits all patients 
Inflammatory processes related to cardiac co-morbidities or diabetes could play a role in the 
clinical effectiveness and financial efficacy of anemia management protocols The incidence 
of erythropoietin hyporesponse coupled with higher ferritin levels creates new issues of 
financial feasibility for components of this protocol, particularly standardized dosing for all 
patients Prospective trials investigating alternate dosing patterns based on the incidence of 
inflammatory conditions are needed to provide evidence that will direct decisions about the 
use of ESA's 
This study examined how nurse-driven approach compares to physician-driven 
practice approach to renal anemia management Evaluation of nurse-driven protocols is 
necessary to determine how the role of the nurse evolves with practice changes and the 
resulting impact on patient care outcomes Using the NREM, the changes in the role of the 
nurse were delineated in each approach to determine if nurse sensitive patient outcomes 
could be identified in the protocol approach This study demonstrated that Hgb levels may 
be attributed to the independent role of nursing and be identified as a nurse sensitive patient 
outcome in nurse-driven renal anemia management 
Anemia management protocols are commonly being used in the hemodialysis setting 
to provide efficient, cost effective renal care Results from this study suggest that using a 
protocol directs nurses in providing renal anemia management in an efficient manner, 
potentially reducing the need for frequent lab testing and nephrologist consultation Cost 
effectiveness of aspects of the nurse-driven protocol was questionable Although iron doses 
77 
were lower and also less costly than the control group, hyporesponse to the ESA could 
potentially be more expensive The use of a RAMP suggests that it is an effective tool with 
potentially higher costs The need to review ESA and iron dosing in the protocol as it relates 
to patient variables such as cardiac or other inflammatory processes is encouraged It is 
evident that more investigation is necessary to establish the relationship between iron and 
epoetin dosing and cost 
A nursing limitation of this study is that the actions of the nurses were not directly 
measured to determine the time, education level, experience, and workload of each nurse and 
its influence on decision-making Although the use of the protocol was as effective as 
traditional physician practice, the impact on the nurses' workload and time management was 
not examined Further research is suggested to directly measure nursing experience, 
education and time as it relates to the use of the protocol and examine its connection with the 
nurse 
There are three further limitations to this study First, only data available in the 
BCPRA PROMIS database was used As a result, data entry may be subject to error, 
omissions may be present and limited standard terminology of variable terms in the database 
all contribute to the quality of the data in this study Second, there were insufficient numbers 
of patients eligible to provide adequate power, particularly in the protocol group A post hoc 
power analysis of/-test difference between two independent means, n=T06,/?= 0 05 and 
effect size = 5 indicated a power of 71% was achieved Low patient numbers eliminated the 
possibility of matching subjects based gender, race and diagnosis They also reduced 
correlation testing possibilities, particularly when gender or race was posed as potential 
confounding variables Although higher sample sizes could have improved power in this 
study and reduced the risk of a Type II error, a false negative conclusion, the retrospective 
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nature of the study in two clinical settings with limited patient populations poses as an 
obstacle to increasing power of the study Third, medical practitioner preferences played a 
role in cost effectiveness Preference of type of intravenous iron ordered by physicians 
increased costs significantly for the control group 
Identifying the most cost effective therapy for renal anemia in the hemodialysis 
setting without compromising efficacy or patient safety is an important objective for health 
care systems The health care system demands that programs demonstrate the impact nursing 
practice changes have on patient outcomes Nursing has a responsibility to ensure that their 
practices provide safe patient care in addition to meeting national standards Evaluating 
practice through patient outcomes achievement is one way to examine nursing practice 
Evaluating patient outcomes in the health care system is an essential part of 
determining the impact of practice change The complexity of the hemodialysis patient 
contributes to the difficulty of examining renal anemia outcomes when implementing a 
protocol This study demonstrated that the use of a nurse-driven RAMP is as effective as a 
traditional physician approach in ensuring that target hemoglobin levels were reached The 
challenge is to look at the multifaceted issue of renal anemia and determine if these protocols 
require modification to better meet the needs of this patient population 
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Appendix A 
RENAL ANEMIA MANAGEMENT PROTOCOL RP010 
0 0 
Notify physician if 
increase tn Hgb 
greater than 20 
from last 
blood work 
Follow 
subsequent 
orders ASSESS 
IRON STATUS 
Refer to page 3 for 
Infufer and 
Venofer Refer to 
page 4 for Ferrlecit 
ASSESS HEMOGLOBIN STATUS 
Target Hgb 110 125 
The following protocol on order of physician transfers anemia management of 
hemodialysis patients to non physician start 0 e RNs and pharmacists) The 
following protocol is intended to serve as a guide and cannot replace clinical 
judgment The recommendations included may be inappropnate for specific 
clinical situations (e g patients with hemochromatosis PRCA allergy to IV iron or 
erythropoietic agents or patients who feel better with higher hemoglobins etc) 
When in doubt please ask a physician or renal pharmacist 
Hgb 126 or Higher and/or Large 
Increase in Hgb {less than 20) 
No EHRT 
required 
Continue 
routine 
monitoring 
of Hgb 
every 4 
weeks 
Reduce dose 
provided there 
have been no dose 
reductions in the 
previous S weeks 
See dose 
adjustment 
schedule (Note 
if there has been a 
dose reduction in 
the previous 5 
weeks maintain 
current dose) 
Recheck Hgb in 2 
weeks 
Hgb 110 - 125 and Hgb Stable (no rise or fall in Hgb greater than 20) 
Receiving EHRT? 
EHRT on hold/discontinued 
HOLD EHRT 
Collect Hgb in 
two weeks 
and then 
Hgb status 
Restart EHRT 
at e reduced 
dose based on 
dosage before 
hold SeedD5» 
adjustironi 
schedule 
Continue 
routine 
monilonrg of 
Hgb every 4 
weeks 
Hgb 109 or Lower and/or Large 
Decrease in Hgb (greater than20) 
Notify (vID for Large Decrease 
in Hgb 
NoEHRT 
required 
Continue 
routine 
monitoring of 
Hgb every 4 
weeks 
Maintain 
dose of 
EHRT and 
continue 
routine 
monitoring 
of Hgb every 
4 weeks 
Restart EHRT at 
reduced dose 
based on dose 
before hold See 
dose adjustment 
schedule Notify 
physician if fall En 
Hgb greater than 
20 from last 
btoodwork 
Recheck Hgb in 4 
weeks 
Continued on page 2 
> 
a 
S3 
£-
> 
ASSESS IRON STATUS Refer to page 3 for Infufer and Venofer Refer to page 4 for Ferrlecit 
NOTE Erythropoietic hormone replacement therapy (EHRT) refers to both Aranesp and Eprex 
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NO 
Notify physician for initiation of erythropoietic 
hormone replacement therapy 
SO 
Target Hgb 110 - 125 should be achieved within 2 
to 4 months of initiating therapy 
Monitor Hgb every 4 weeks or as clinically 
indicated (no earlier than 2 weeks after a dose 
change) 
Hgb 109 or lower and/or 
Large decrease in Hgb 
(greater than 20) 
Notify physician if Hgb is less 
than 90 or if fall in Hgb is 
greater than 20 from last 
Woodwork Follow subsequent 
orders ACCESS IRON 
STATUS 
Refer to page 3 for Dexiron 
and Venofer Refer to page 4 
for Ferrlecit 
Increase dose provided there has been no dose 
increase in the previous 5 weeks* See dose 
adjustment schedule Notify nephrologist if 
patient s hemoglobin is not within target after 3 
consecutive dose increases 
NOTE If them has been a dose reduction in 
the previous 5 weeks maintain current dose 
Continue monitonng of Hgb every 4 weeks or as 
clinically indicated 
ASSESS IRON STATUS 
Refer to page 3 for Infufer and Venofer 
Refer to page 4 for Ferneat 
*lf Aranesp™ dose is 150mcg/week or if 
Eprex® dose is 10 000 units 3x per week for 
B weeks or more and hemoglobin less than 
110 contact nephrologist 
Follow this algor i thm for Iron 
Dextran and Iron Sucrose (must 
be given after a test dose) 
(Refer to page 4 for Ferrlecit) 
ASSESS IRON STATUS-
NOTE If TSat and ferritin values indicate both an overload and Ihe need 
for iron replacement (i e TSat less than 20% and Ferritin greater than 
500) please contact physician for further orders 
TSat greater than 50% 
OR 
Ferritin greater than 
500 
TSat less than 20% 
OR 
Femtin less than 200 
REPLACEMENT OF IRON 
AND 
TSat over 20% 
Ferntm 200 - 500 
HOLD PO/IV IRON 
Collect iron bloodwork 
in 4 weeks and 
ASSESS IRON 
STATUS 
Initiate IV iron at a dose 
of 100mg2x/wkfor5 
weeks Check iron 
bloodwork 2 week after 
last dose and 
ASSESS IRON 
STATUS 
If receiving 
maintenance iron 
continue current 
maintenance 
dosage 
NOTE Patient not to receive more than 4 
courses or iron replacement in a row Notify 
physician if iron indicies remain low after 20 
consecutive weeks of iron 100 mg 2x/wk 
If just completed 
100 mg 2x /wk fo r 
5 weeks initiate 
maintenance IV 
iron at 100 mg 
q 2 weeks 
If Iron Is currently 
on hold restart Iron 
at half the frequency 
but same dose (e g 
100 mg q2 monthly) 
This dose becomes 
the patient s new 
maintenance dose 
MONITOR 
TSat and ferritin every 3 months and 
'If iron bloodwork ever appears very unusual compared to previous results (e g with replacement of 
Iron stores TSat aoes from areater than 20% to less than 50%) reoeat bloodwork and reassess iron 
If not receiving IV 
iron initiate 
maintenance IV 
iron at 100 mg 
q 2 weeks 
Note Iron maintenance dose refers to 100 q monthly unless otherwise indicated 
Infufer refers to Iron Dextran 
Venofer refers to Iron Sucrose 
NORTHERN RENAL PROGRAM 
Follow this algor i thm 
for Ferr leci t 
(Refer to page 3 for Iron Dextran 
and Iron Sucrose) 
ASSESS IRON STATUS" 
NOTE If TSat and ferritin values indicate both an overload and Ihe need 
for i ron replacement (i e TSat less than 20% and Ferritin greater than 
500) please contact physician for further orders 
TSat greater than 50% 
OR 
Ferntin greater than 
500 
HOLD PO/IV IRON 
Collect iron bloodwork 
in 4 weeks and 
ASSESS IRON 
STATUS 
TSat less than 20% 
OR 
Ferntin less than 200 
REPLACEMENT OF IRON 
Initiate IV iron at a dose 
of 125 mg 2x/wk for 5 
weeks Check iron 
bloodwork 2 weeks 
after last dose and 
ASSESS IRON 
STATUS 
if receiving 
maintenance i ron 
continue current 
maintenance 
dosage 
NOTE Patient not to receive more than 4 
courses or iron replacement in a row Notify 
physician if iron indlcies remain low after 20 
consecutive weeks of iron 126 mg 2x/wk 
AND 
TSat over 20% 
Ferritin 200 - 500 
If jus t completed 
125mg 2x /wk fo r 
5 weeks initiate 
maintenance IV 
iron at 62 5 mg 
q 2 weeks 
If iron is currently 
on hold restart Iron 
at half the frequency 
but same dose (e g 
125 mgq monthly) 
This dose becomes 
the patient s new 
maintenance dose 
MONITOR 
TSat and ferntin every 3 months and 
If not receiving IV 
iron initiate 
maintenance IV 
iron at 125 mg 
q 2 weeks 
*lf Iron bloodwork ever appears very unusual compared to previous results (e g with replacement of 
iron stores TSat aoes from areater than 20% to less than 50%) reoeat bloodwork and reassess iron 
Note Iron maintenance dose refers to 125 q monthly unless otherwise indicated 
NORTHERN RENAL PROGRAM 
DOSE ADJUSTMENT SCHEDULE FOR PATIENTS USING EPREX (ERYTHROPOIETIN) 
The following chart provides the necessary 
changes for most dose increments or dose 
reductions If the patient's dosing does not 
fall into one of the intervals, contact the 
nephrologist 
Eprex is available in multidose vials (20,000 
units/mL) 
. 2,000 units (0 1 mL) 
• 3,000 units (0 15 mL) 
• 4,000 units (0 2 mL) 
• 5,000 units (0 25 mL) 
• 6,000 units (0 3 mL) 
• 8, 000 units (0 4 mL) 
. 9,000 units (0 45 mL) and 
. 10,000 units (0 5 mL) 
Curt en t Dose 
2,000 units/wk 
3,000 units/wk 
4,000 units/wk 
6,000 units/wk 
4,000 IU 2x/wk 
5,000 IU 2x/wk 
6,000 IU 2x/wk 
8,000 IU 2x/wk 
9,000 IU 2x/wk 
10,000 IU 2x/wk 
8,000 IU 3x/wk 
10,000 IU 3x/wk 
Increase Dose To 
3,000 units/wk 
4,000 units/wk 
6,000 units/wk 
4,000 units 2x/wk 
5,000 IU 2x/wk 
6,000 IU 2x/wk 
8,000 IU 2x/wk 
9,000 IU 2x/wk 
10,000 IU 2x/wk 
8,000 IU 3x/wk 
10,000 IU 3x/wk 
Contact nephrologist 
Reduce Dose To 
Discontinue Eprex 
2,000 units/wk 
3,000 units/wk 
4,000 units/wk 
6,000 lU/wk 
4 000 IU 2x/wk 
5,000 IU 2x/wk 
6,000 IU 2x/wk 
8,000 IU 2x/wk 
9,000 IU 2x/wk 
10,000 IU2x/wk 
8,000 IU 3x/wk 
Developed by PGRH Renal Pharmacist 
Approved by Regional P & T Committee on May 17, 2007 
May proposal 
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DOSE ADJUSTMENT SCHEDULE FOR PATIENTS USING ARANESP (DARBEPOIETIN) 
The following chart provides the necessary 
changes for most dose increments or dose 
reductions If the patient's dosing does not 
fall into one of the intervals, contact the 
nephrologist 
The following Aranesp pre-filled syringes are 
available 
• 10 meg 
• 20 meg 
• 30 meg 
• 40 meg 
• 50 meg 
« 60 meg 
• 80 meg 
• 100 meg and 
• 150 meg 
Cm rent Dose/WK 
10 mcg/q2wk 
10 meg/wk 
20 meg/wk 
30 meg/wk 
40 meg/wk 
50 meg/wk 
60 meg/wk 
80 meg/wk 
100 meg/wk 
150 meg/wk 
Increase Dose To 
10 meg/wk 
20 meg/wk 
30 meg/wk 
40 meg/wk 
50 meg/wk 
60 meg/wk 
80 meg/wk 
100mcg/wk 
150 meg/wk 
Contact nephrologist 
Reduce Dose To 
Discontinue Aranesp™ 
10 mcg/q2wk 
10 meg/wk 
20 meg/wk 
30 meg/wk 
40 meg/wk 
50 meg/wk 
60 meg/wk 
80 meg/wk 
100 meg/wk 
Appendix B 
3 C R e n a l A g = n C / 
Scorn MO-16 IOS Sur i rd i i r -
V .incline- 3C \r,z i 
TJ i60J,63l 3-1 • rax i W H . l u 
t mail acpriucneos _cc . 
Consent for Use of Data -_-
Patient Record and Outcome Management information System 
As an individual requiring renal services in the Province of British Columbia, 
I, understand that information regarding my 
clinical, laboratory, and treatment regimens will be entered in a provincial database 
This information will not be accessible by any members of the public and will remain 
anonymous This information may be used for statistical purposes, but I will not be 
identified as an individual at any time 
The purpose of this information is to ensure state of the art delivery of care and to 
provide my caregivers with efficient, timely and accurate information about my health 
today and into the future 
By signing this form I acknowledge that my caregivers, the statistical analysts and data 
managers in charge of the Patient Information System may have access to my 
personal information 
SIGNATURE 
DATE 
WITNESS 
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Appendix C 
From Lee Er (Renal) [ler@bcpra ubc ca] 
Sent September-03-08 9 41 AM 
To sushila@shaw ca 
Subject RE Anemia management study 
To Whom It May Concern, 
This is to confirm that any access or release of PROMIS data for research 
purposes will be proceeded upon the approval of the ethics board on the 
project A copy of the ethics' approval must be faxed to BC Renal Agency at 
604-806-8005 Only data related to the research project for the prespecified 
hospital/region, without any subject identifier information (e g PHN, Names, 
Date of Birth), will be released 
Thank you, 
Mirek Piaseczny 
Director of Information and Statistics 
BC Renal Agency 
An agency of the Provincial Health Services Authority 
570 14 - 1081 Burrard Street 
Vancouver, BC,V6Z1Y6 
tel (604)806-8647 
fax (604)806-8005 
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Appendix D 
UNIVERSITY OF NORTHERN BRITISH COLUMBIA 
RESEARCH ETHICS BOARD 
MEMORANDUM 
To* Sushila Saunders 
CC* Martha MacLeod 
From: Henry Harder, Chair 
Research Ethics Board 
Date. June 8, 2009 
Re: E2009.0602.094 
Anemia management protocols in the care of hemodialysis patients 
Examining patient outcomes 
Thank you for submitting the above-noted proposal to the Research Ethics Board Your 
proposal has been approved 
We are pleased to issue approval for the above named study for a period of 12 months from 
the date of this letter Continuation beyond that date will require further review and renewal 
of REB approval Any changes or amendments to the protocol or consent form must be 
approved by the Research Ethics Board 
Good luck with your research 
Sincerely, 
Henry Harder 
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Appendix E 
Northern Health Corporate Office 
600-299 Victoria Street, Prince George, BC V2L 5B8 
Telephone (250) 565-2649, Fax (250) 565-2640, www northernhealth ca 
June 29, 2009 File #RRC-2009-0020 
Sushila Saunders 
4435 Otway Rd 
Prince George BC V2M 6X6 
Dear Sushila 
RE: Anemia management protocols in the care of hemodialysis patients: Examining 
patient outcomes 
On behalf of the Northern Health Research Review Committee, I would like to thank you for 
your submission titled 
"Anemia management protocols in the care of hemodialysis patients Examining 
patient outcomes " 
Your study has met the requirements of the Northern Health Research Review Committee 
and you may proceed 
Enjoy your work' We look forward to hearing about your findings 
Sincerely, 
Suzanne Johnston, Chair, NH Research Review Committee 
Vice President, Academic Affairs and Chief Nursing Officer 
SJ/sw 
CC Laurie Ledger 
File 
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Appendix F 
Levene's test for Equality of Variances for Hgb t-test 
Month 
October mean Hgb 1 127 291 
November mean Hgb 1 975 163 
December mean Hgb 341 561 
January mean Hgb 042 837 
February mean Hgb 071 790 
March mean Hgb 1559 215 
April mean Hgb 456 501 
May mean Hgb 687 409 
June mean Hgb 611 436 
July mean Hgb 1029 313 
August mean Hgb 321 572 
September mean Hgb 3 146 079 
Effect Size of the Difference Between the Means of Hemoglobin Levels 
Month Mean difference SD Cohen's d 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
-140 
-43 
3 43 
-27 
3 63 
01 
-1 85 
93 
99 
-197 
-169 
-3 11 
15 18 
14 00 
13 17 
14 12 
14 10 
14 16 
13 19 
14 37 
14 07 
12 70 
12 07 
12 71 
09 
03 
26 
02 
26 
01 
14 
06 
07 
16 
14 
24 
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Independent Samples t-test for Equality of Means 
Month 
October mean Hgb 
November mean Hgb 
December mean Hgb 
January mean Hgb 
February mean Hgb 
March mean Hgb 
April mean Hgb 
May mean Hgb 
June mean Hgb 
July mean Hgb 
August mean Hgb 
September mean Hgb 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
Equal variances 
assumed 
t 
-488 
-165 
1009 
-097 
1326 
003 
-700 
340 
346 
-723 
-635 
-1265 
df 
100 
100 
80 
101 
100 
86 
94 
102 
94 
88 
87 
99 
p (2 tailed) 
627 
870 
316 
923 
188 
997 
485 
735 
730 
472 
527 
209 
109 
Appendix G 
Hemoglobin Categories-October 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within Oct 
Hgb 
% of Total 
Count 
Expected Count 
% within case 
% withm Oct 
Hgb 
% of Total 
75-109 
22 
212 
37 3 
61 1 
22 0 
14 
14 8 
34 1 
38 9 
14 0 
110-125 
27 
27 7 
45 8 
57 4 
27 0 
20 
19 3 
48 8 
42 6 
20 0 
126-145 
10 
10 0 
169 
58 8 
10 0 
7 
70 
17 1 
41 2 
70 
Total 
59 
59 0 
100 0 
59 0 
59 0 
41 
410 
100 0 
41 0 
41 0 
Hemoglobin Categories-November 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within NovHgb 
% of Total 
Count 
Expected Count 
% within case 
% within NovHgb 
% of Total 
75-109 
18 
16 7 
29 5 
64 3 
176 
10 
113 
24 4 
35 7 
98 
110-125 
30 
32 9 
49 2 
54 5 
29 4 
25 
22 1 
610 
45 5 
24 5 
126-145 
13 
11 4 
21 3 
68 4 
12 7 
6 
76 
14 6 
316 
59 
Total 
61 
610 
100 0 
59 8 
59 8 
41 
41 0 
100 0 
40 2 
40 2 
Hemoglobin Categories- December 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within DecHgb 
% of Total 
Count 
Expected Count 
% within case 
% within DecHgb 
% of Total 
75-109 
18 
198 
310 
66 7 
22 8 
9 
72 
42 9 
33 3 
114 
110-125 
27 
25 0 
46 6 
79 4 
34 2 
7 
90 
33 3 
20 6 
89 
126-145 
13 
13 2 
22 4 
72 2 
16 5 
5 
48 
23 8 
27 8 
63 
Total 
58 
58 0 
100 0 
73 4 
73 4 
21 
210 
100 0 
26 6 
26 6 
Hemoglobin Categories-January 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within Jan_Hgb 
% of Total 
Count 
Expected Count 
% within case 
% within JanHgb 
% of Total 
75-109 
17 
169 
28 8 
60 7 
173 
11 
11 1 
28 2 
39 3 
112 
110-125 
25 
24 7 
42 4 
610 
25 5 
16 
16 3 
41 0 
39 0 
16 3 
126-145 
17 
175 
28 8 
58 6 
173 
12 
11 5 
30 8 
414 
12 2 
Total 
59 
59 0 
100 0 
60 2 
60 2 
39 
39 0 
100 0 
39 8 
39 8 
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Hemoglobin Categories- February 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within 
FebHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
FebHgb 
% of Total 
75-109 
14 
14 5 
24 6 
56 0 
14 3 
11 
105 
26 8 
44 0 
11 2 
110-125 
30 
30 2 
52 6 
57 7 
30 6 
22 
218 
53 7 
42 3 
22 4 
126-145 
13 
12 2 
22 8 
619 
13 3 
8 
88 
195 
38 1 
82 
Total 
57 
57 0 
100 0 
58 2 
58 2 
41 
41 0 
100 0 
41 8 
41 8 
Hemoglobin Categories- March 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within 
Mar_Hgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
MarHgb 
% of Total 
75-109 
17 
159 
28 3 
73 9 
195 
6 
7 1 
22 2 
26 1 
69 
110-125 
26 
29 0 
43 3 
619 
29 9 
16 
13 0 
59 3 
38 1 
184 
126-145 
17 
152 
28 3 
77 3 
19 5 
5 
68 
185 
22 7 
57 
Total 
60 
60 0 
100 0 
69 0 
69 0 
27 
27 0 
100 0 
310 
310 
Hemoglobin Categories- April 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within 
AprHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
AprHgb 
% of Total 
75-109 
15 
144 
25 0 
65 2 
15 6 
8 
86 
22 2 
34 8 
83 
110-125 
31 
30 6 
51 7 
63 3 
32 3 
18 
184 
50 0 
36 7 
18 8 
126-145 
14 
15 0 
23 3 
58 3 
14 6 
10 
90 
27 8 
41 7 
104 
Total 
60 
60 0 
100 0 
62 5 
62 5 
36 
36 0 
100 0 
37 5 
37 5 
Hemoglobin Categories-May 
Control group 
Protocol group 
Count 
Expected Count 
% withm case 
% within 
MayHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
MayHgb 
% of Total 
75-109 
17 
172 
28 3 
58 6 
16 8 
12 
11 8 
29 3 
414 
11 9 
110-125 
29 
30 9 
48 3 
55 8 
28 7 
23 
21 1 
56 1 
44 2 
22 8 
126-145 
14 
119 
23 3 
70 0 
13 9 
6 
81 
14 6 
30 0 
59 
Total 
60 
60 0 
100 0 
59 4 
59 4 
41 
410 
100 0 
40 6 
40 6 
Hemoglobin Categories-June 
75-109 110-125 126-145 Total 
22 
22 1 
36 7 
62 9 
23 2 
13 
12 9 
37 1 
37 1 
24 
23 4 
40 0 
64 9 
25 3 
13 
13 6 
37 1 
35 1 
14 
14 5 
23 3 
60 9 
14 7 
9 
85 
25 7 
39 1 
60 
60 0 
100 0 
63 2 
63 2 
35 
35 0 
100 0 
36 8 
13 7 13 7 95 36 8 
75-109 110-125 126-145 Total 
Control group 
Protocol group 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within 
JunHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
JunHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
JulHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
JulHgb 
% of Total 
% of Total 
22 26 
22 4 25 8 
36 1 42 6 
66 7 68 4 
24 4 28 9 
11 12 
106 122 
37 9 414 
33 3 316 
122 133 
36 7 42 2 
13 61 
12 9 610 
213 100 0 
68 4 67 8 
14 4 67 8 
6 29 
6 1 29 0 
20 7 100 0 
316 32 2 
6 7 32 2 
211 100 0 
Hemoglobin Categories-July 
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Hemoglobin Categories-August 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within 
AugHgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
AugHgb 
% of Total 
75-109 
22 
20 0 
37 9 
73 3 
25 3 
8 
10 0 
27 6 
26 7 
92 
110-125 
27 
27 3 
46 6 
65 9 
310 
14 
13 7 
48 3 
34 1 
16 1 
126-145 
9 
10 7 
15 5 
56 3 
10 3 
7 
53 
24 1 
43 8 
80 
Total 
58 
58 0 
100 0 
66 7 
66 7 
29 
29 0 
100 0 
33 3 
33 3 
Hemoglobin Categories-September 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within 
Sep_Hgb 
% of Total 
Count 
Expected Count 
% within case 
% within 
SepHgb 
% of Total 
75-109 
24 
20 1 
39 3 
72 7 
24 0 
9 
12 9 
23 1 
27 3 
90 
110-125 
25 
29 9 
410 
510 
25 0 
24 
19 1 
61 5 
49 0 
24 0 
126-145 
12 
110 
19 7 
66 7 
12 0 
6 
70 
154 
33 3 
60 
Total 
61 
610 
100 0 
610 
610 
39 
39 0 
100 0 
39 0 
39 0 
Chi-Square Test of Lower than, on Target and Higher than Target Hemoglobin Data 
Month 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
n 
100 
102 
79 
98 
98 
87 
96 
101 
95 
90 
87 
100 
Chi-Square 
value 
133 
1454 
1270 
044 
174 
1951 
262 
1223 
099 
029 
1393 
4 200 
df 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
p (2 sided) 
945 
483 
530 
978 
917 
377 
877 
542 
951 
985 
498 
122 
116 
Appendix H 
On/Off Target Hemoglobin Categories-October 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within October target 
% of Total 
Count 
Expected Count 
% within case 
% within October target 
% of Total 
110-125 
27 
28 1 
44 3 
57 4 
26 5 
20 
189 
48 8 
42 6 
196 
<110or >125 
34 
32 9 
55 7 
61 8 
33 3 
21 
22 1 
51 2 
38 2 
20 6 
Total 
61 
610 
100 0 
59 8 
59 8 
41 
41 0 
100 0 
40 2 
40 2 
On/Off Target Hemoglobin Categories-November 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within November 
target 
% of Total 
Count 
Expected Count 
% within case 
% within November 
target 
% of Total 
110-125 
30 
32 9 
49 2 
54 5 
29 4 
25 
22 1 
610 
45 5 
24 5 
<110or>125 
31 
28 1 
50 8 
66 0 
30 4 
16 
189 
39 0 
34 0 
15 7 
Total 
61 
610 
100 0 
59 8 
59 8 
41 
41 0 
100 0 
40 2 
40 2 
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On/Off Target Hemoglobin Categories December 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within December target 
% of Total 
Count 
Expected Count 
% within case 
% within December target 
% of Total 
110-125 
27 
25 3 
44 3% 
79 4% 
32 9% 
7 
87 
33 3% 
20 6% 
8 5% 
<110or>125 
34 
35 7 
55 7% 
70 8% 
41 5% 
14 
12 3 
66 7% 
29 2% 
17 1% 
Total 
61 
610 
100 0% 
74 4% 
74 4% 
21 
210 
100 0% 
25 6% 
25 6% 
On/Off Target Hemoglobin Categories-January 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within January target 
% of Total 
Count 
Expected Count 
% within case 
% within January target 
% of Total 
110-125 
25 
24 3 
41 0% 
61 0% 
24 3% 
16 
16 7 
38 1% 
39 0% 
15 5% 
<110or>125 
36 
36 7 
59 0% 
58 1% 
35 0% 
26 
25 3 
61 9% 
41 9% 
25 2% 
Total 
61 
610 
100 0% 
59 2% 
59 2% 
42 
42 0 
100 0% 
40 8% 
40 8% 
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On/Off Target Hemoglobin Categories-February 
Control group Count 
Expected Count 
% within case 
% within Feb target 
% of Total 
Protocol group Count 
Expected Count 
% withm case 
% within Feb target 
% of Total 
110-125 
30 
30 6 
50 0% 
57 7% 
29 4% 
22 
214 
52 4% 
42 3% 
21 6% 
<110or>125 
30 
29 4 
50 0% 
60 0% 
29 4% 
20 
20 6 
47 6% 
40 0% 
19 6% 
Total 
60 
60 0 
100 0% 
58 8% 
58 8% 
42 
42 0 
100 0% 
41 2% 
41 2% 
On/Off Target Hemoglobin Categories March 
110-125 <110 or > 125 Total 
Control group Count 26 
Expected Count 29 1 
% within case 42 6% 
% within March target 61 9% 
% of Total 29 5% 
Protocol group Count 16 
Expected Count 12 9 
% within case 59 3% 
% withm March target 3 8 1 % 
% of Total 18 2% 
35 
319 
57 4% 
76 1% 
39 8% 
11 
14 1 
40 7% 
23 9% 
12 5% 
61 
610 
100 0 
% 
69 3% 
69 3% 
27 
27 0 
100 0 
% 
30 7% 
30 7% 
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On/Off Target Hemoglobin Categories-April 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within April target 
% of Total 
Count 
Expected Count 
% within case 
% within April target 
% of Total 
110-125 
31 
30 6 
51 7% 
63 3% 
32 3% 
18 
184 
50 0% 
36 7% 
18 8% 
<110or>125 
29 
29 4 
48 3% 
61 7% 
30 2% 
18 
176 
50 0% 
38 3% 
18 8% 
Total 
60 
60 0 
100 0% 
62 5% 
62 5% 
36 
36 0 
100 0% 
37 5% 
37 5% 
On/Off Target Hemoglobin Categories-May 
Control group Count 
Expected Count 
% within case 
% within May target 
% of Total 
Protocol group Count 
Expected Count 
% within case 
% within May target 
110-125 -
29 
30 5 
47 5% 
55 8% 
27 9% 
23 
215 
53 5% 
44 2% 
<110or>125 
32 
30 5 
52 5% 
61 5% 
30 8% 
20 
21 5 
46 5% 
38 5% 
Total 
61 
610 
100 0% 
58 7% 
58 7% 
43 
43 0 
100 0% 
41 3% 
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On/Off Target Hemoglobin Categories June 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within June target 
% of Total 
Count 
Expected Count 
% within case 
% within June target 
% of Total 
110-125 
24 
23 5 
39 3% 
64 9% 
25 0% 
13 
13 5 
37 1% 
35 1% 
13 5% 
<110or>125 
37 
37 5 
60 7% 
62 7% 
38 5% 
22 
215 
62 9% 
37 3% 
22 9% 
Total 
61 
610 
100 0% 
63 5% 
63 5% 
35 
35 0 
100 0% 
36 5% 
36 5% 
On/Off Target Hemoglobin Categories July 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within July 
target 
% of Total 
Count 
Expected Count 
% within case 
% within July 
target 
% of Total 
110-125 
26 
25 8 
42 6% 
68 4% 
28 9% 
12 
12 2 
41 4% 
31 6% 
13 3% 
<110or>125 
35 
35 2 
57 4% 
67 3% 
38 9% 
17 
16 8 
58 6% 
32 7% 
18 9% 
Total 
61 
610 
100 0% 
67 8% 
67 8% 
29 
29 0 
100 0% 
32 2% 
32 2% 
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On/Off Target Hemoglobin Categories August 
Control group 
Protocol group 
Count 
Expected Count 
% withm case 
% within August 
target 
% of Total 
Count 
Expected Count 
% within case 
% within August 
target 
% of Total 
110-125 
27 
26 7 
46 6% 
65 9% 
30 3% 
14 
14 3 
45 2% 
34 1% 
15 7% 
<110or>125 
31 
31 3 
53 4% 
64 6% 
34 8% 
17 
16 7 
54 8% 
35 4% 
19 1% 
Total 
58 
58 0 
100 0% 
65 2% 
65 2% 
31 
310 
100 0% 
34 8% 
34 8% 
On/Off Target Hemoglobin Categories September 
Control group 
Protocol group 
Count 
Expected Count 
% within case 
% within September 
target 
% of Total 
Count 
Expected Count 
% within case 
% within September 
target 
% of Total 
110-125 
25 
29 6 
41 0% 
51 0% 
24 8% 
24 
194 
60 0% 
49 0% 
23 8% 
<110or>125 
36 
314 
59 0% 
69 2% 
35 6% 
16 
20 6 
40 0% 
30 8% 
15 8% 
Total 
61 
610 
100 0% 
60 4% 
60 4% 
40 
40 0 
100 0% 
39 6% 
39 6% 
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Chi-Square Test of On/Off Categorical Hemoglobin Data 
Month n Chi-Square df p (2 sided) 
value 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
102 
102 
82 
103 
102 
88 
96 
104 
96 
90 
89 
101 
0 201 ] 
1373 
0 769 ] 
0 087 
0 056 
2 076 
0 025 
0 357 
0 046 
0 012 
0016 1 
3 498 1 
[ 654 
I 241 
I 381 
I 769 
I 813 
1 150 
1 874 
I 550 
1 831 
I 911 
[ 900 
1 061 
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Appendix I 
Levene's Test for Equality of Variances for Epoetin Alfa Mean Dose in Control and Protocol 
Groups 
Month Equal variances 
October mean Epoetin Alfa dose 
November mean Epoetin Alfa dose 
December mean Epoetin Alfa dose 
January mean Epoetin Alfa dose 
February mean Epoetin Alfa dose 
March mean Epoetin Alfa dose 
April mean Epoetin Alfa dose 
May mean Epoetin Alfa dose 
June mean Epoetin Alfa dose 
July mean Epoetin Alfa dose 
August mean Epoetin Alfa dose 
September mean Epoetin Alfa dose 
assumed 
assumed 
assumed 
assumed 
assumed 
assumed 
not assumed 
not assumed 
not assumed 
assumed 
assumed 
assumed 
1454 
2 262 
2 639 
2 063 
3 857 
2 850 
7 677 
8 364 
4 749 
3 072 
2 246 
2 240 
231 
136 
108 
154 
053 
095 
007 
005 
032 
083 
137 
138 
Effect Size of the Difference Between the Means of Epoetin Alfa 
Month 
October 
November 
December 
January 
February 
March 
April 
May 
June 
July 
August 
September 
Mean 
difference 
1 14 
1 12 
1 52 
-125 
-4 08 
-5 86 
-102 
-103 
-1 11 
-107 
-105 
-9 41 
SD 
3 00 
3 11 
3 08 
3 19 
3 24 
3 34 
3 28 
331 
3 30 
3 35 
3 40 
3 38 
Cohen's d 
38 
36 
49 
39 
126 
175 
32 
31 
34 
32 
31 
2 78 
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